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ABSTRACT 
In this PhD project we dealt with β-sitosterol, resveratrol and quercetin, three natural substances featuring 
ascertained biological activities. These compounds are characterized by a limited bioavailability and a low 
stability: these features reduce their application in pharmaceutical, nutraceutical and dermocosmetic areas. 
In order to improve the above mentioned properties, we synthesized esters of these compounds, following 
either a chemical approach (resveratrol, quercetin, and β-sitosterol) and a enzymatic approach (resveratrol 
and β-sitosterol). The esterification was performed with saturated (palmitic and stearic) and unsaturated 
(oleic, linoleic and linolenic) fatty acids: this synthesis introduced in a single molecule (prodrug) two 
moieties both pharmacologically active.  
Chemical synthesis was used to obtain resveratrol triesters, but failed with diesters: so these derivatives 
were synthesized by enzymatic approach. 
1
H-NMR and 13C-NMR analyses allowed to define the structure of 
these derivatives.  
The synthesis  of quercetin penta, tetra and triesters was obtained by modulating the acid/quercetin molar 
ratio; mono- and bi-dimensional NMR techniques were used to determine the structure of all quercetin 
esters, while for triester computational studies were needed. 
In addition, for resveratrol and quercetin esters the antioxidant activity was evaluated: this property was 
not increased by esterification. Also the bioavailability was studied for resveratrol and its trioleoyl ester, 
but the resveratrol resulted more bioavailable in comparison with its ester. 
 In order to improve drug topical delivery, quercetin and its derivatives were also incorporated in liposome 
formulations.  
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1 - INTRODUCTION 
 
 
In recent years, the interest for natural substances with beneficial activity in human, and in particular for 
the ones  that are useful to counteract aging, has sharply risen. In fact, there is a significant increase in skin 
cosmetic, nutraceuticals and even pharmaceutical products, based on natural compounds or on their semi-
synthetic derivatives. The main interest has been observed for natural substances with strong anti-oxidant 
activity, because oxidative stress induced by multiple factors is the main cause of many pathological 
conditions: inflammation, cancer, coronary heart disease and even skin aging.  
In this PhD work we dealt with three natural compounds: β-sitosterol, resveratrol and quercetin, 
substances featuring biological activities which are ascertained and described in literature. 
β-sitosterol is the most abundant phytosterol; plant sterols are structurally similar to cholesterol and a 
recent epidemiological study have shown an inverse relation between phytosterol consumption and serum 
cholesterol. In addition, growing evidence suggests that phytosterols have preventive effects against cancer 
of the lung, stomach, ovary and estrogen-dependent human breast cancer. Phytosterols consumption may 
also increase the activity of antioxidant enzymes and thereby reduce oxidative stress. 
Resveratrol, a natural polyphenol present in several plants, especially in grapes, has been shown to have a 
number of physiological properties such as antioxidant, anti-inflammatory and antitumor activities. In 
addition, resveratrol was identified as the most potent activator of SIRT1, a protein possessing NAD
+
-
dependent deacetylase activity. SIRT1 plays a context-dependent role in health span regulation, for 
instance by mediating effects in metabolic stress situations, such as high-fat-diet-induced obesity, glucose 
intolerance and cancer. Resveratrol has been shown to have a preventive effect on photoaging and 
photocarcinogenesis as well, in fact the topical application of this polyphenol was found to inhibit skin 
edema, inflammation, peroxidation, protein expression induced by UVB irradiation. 
Quercetin is a natural polyphenol, but unlike resveratrol, it belongs to the flavonoid family. Flavonoids are 
found in a wide variety of fruits and vegetables, either as glycosides (bound to a sugar moiety) or as 
aglycones (without sugar groups). Quercetin has been shown to possess several biological properties, such 
as antioxidant, antithrombotic, antihypertensive, antitumor and antiallergic activities. In addition, topical 
application of quercetin inhibits oxidative skin damage and the inflammatory process induced by solar UV 
radiation. 
Although these compounds are present in significant amounts in foods, their dietary intake is generally 
characterized by a low bioavailability, either due to their low absorption and to the high rate with which 
they are metabolized, mainly by methylation, sulfation and glucuronidation of -OH groups. These factors 
reduce the potential preventive and therapeutic activities of these classes of molecules, hampering their 
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use in pharmaceutical and nutraceutical areas. Their dermocosmetic application is reduced by their low 
skin permeability and poor solubility in water media, making the development of pharmaceutical 
formulations difficult. 
The aim of this PhD project is to modify the structure of the three investigated compounds in order to 
improve their solubility, bioavailability and stability, leading to the development of a number of semi-
synthetic compounds. In drugs containing carboxylic and hydroxylic groups, esterification represents one of 
the main reactions in organic synthesis used to improve the above mentioned properties.  
We decided to esterify these natural substances with saturated and unsaturated fatty acids, especially ω-3 
and ω-6. This would introduce in a single molecule (prodrug) two moieties both pharmacologically active. 
Fatty acids are a class of compounds with interesting pharmacological properties, such as cardiovascular 
activity and structural function especially in the skin. In fact, palmitic acid (C16:0), stearic acid (C18:0), oleic 
acid (C18:1), linoleic acid (C18:2), and (all-cis)-11,14,17-eicosatrienoic acid (ETA, C20:3n-3) were 
determined as major fatty acid components in human epidermis; the levels of saturated fatty acids (such as 
palmitic and stearic acids) and unsaturated fatty acids (such as linoleic acid and ETA) result to be decreased 
in aged skin compared with those in young skin.  
In this PhD project we looked at the development of esterification processes of β-sitosterol, resveratrol and 
quercetin with fatty acids and the analytical characterization of the compounds obtained. 
The esterification of β-sitosterol with fatty acids was performed either by chemical and enzymatic 
approach. The β-sitosterol esters chemically synthesized were used as reference standards for the 
determination of the esters enzymatically obtained.  
Every attempt of chemical esterification of resveratrol led indistinctly to the synthesis of the triester, even 
by modulating the molar ratio of acid vs. resveratrol. To obtain the mono and di derivatives we went to a 
biosynthetic approach: starting from the triester, in appropriate conditions and using suitable enzymes, we 
were able to synthesize and to characterize partially hydrolyzed derivatives of resveratrol. 
Following a similar approach, the chemical esterification of quercetin led to the formation of completely 
esterified quercetin. By modulating the molar ratios between quercetin and fatty acid, on the contrary, a 
mixture of tri, tetraester was obtained. To identify non-esterified groups of quercetin, mono- and bi-
dimensional NMR techniques were used: this allowed us to determine the structure of tetraester, while the 
structure of triester was determined by computational studies.  
In addition, for the esters obtained from resveratrol and quercetin some pharmacological properties such 
as antioxidant activity and bioavailability were assessed, and liposome formulation trials were carried out. 
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1.1 - β-SITOSTEROL 
 
Sterols in plants have cellular functions analogous to those of cholesterol in animals. β-sitosterol (Fig. 1) is 
the most common sterol in plants; it differs from cholesterol for the ethyl group at C-21. Hydrogenation of 
the 6, 7 double bond of β-sitosterol converts it into sitostanol. 
 
 
 
 
 
 
 
 
Figure 1. 
 
In plants, sterols have both a structural function and a metabolic role. They are integral membrane 
components which regulate the membrane fluidity and permeability, affecting various functions such as 
simple diffusion, carrier-mediated diffusion and active transport across the membrane. They also modulate 
the activities of membrane-associated proteins including enzymes, receptors and signal transduction 
components. In addition, they are precursors of other bioactive steroids, such as the so-called 
brassinosteroids (a special class of growth substances), and substrates for the synthesis of numerous 
secondary plant metabolites [1]. 
Vegetable oils and cereals are generally known to be the best natural sources of dietary plant sterols [2]. 
Plant sterols occur both as free sterols and as bound conjugates, i.e., fatty acid esters (mainly C-16 and C-18 
fatty acids), esters of phenolic acids, glycosides (most commonly with β-D-glucose) and acylated glycosides 
(esterified at the 6-hydroxy group of the sugar moiety) [3]. The sterol content in a given plant may vary 
depending on many factors, such as genetic background, growing conditions, tissue maturity and 
postharvest changes [2]. 
 
1.1.1 - BIOLOGICAL ACTIVITIES 
Cardiovascular activity 
There is a scientific consensus that reduction of low density lipoprotein (LDL) cholesterol is important for 
coronary risk decrease. Dietary cholesterol intake is variable but is often less than 300 mg/day and 
currently 200 mg/day is recommended. Approximately 25% of the plasma cholesterol is due to dietary 
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intake, while 75% is accounted by endogenous synthesis [4]. However, dietary cholesterol appears to be 
quite important because it is inversely correlated with endogenously synthesized cholesterol, suggesting 
that they are co-regulated [5]. Phytosterols are thought to act primarily in the intestinal lumen. As 
cholesterol analogs, they compete with it in absorptive micelles resulting in a reduced solubility of 
cholesterol [6]. The affinity of plant sterols for micelles is greater than that of cholesterol. Human 
physiological studies showed that the inclusion of phytosterols in a test meal resulted in the reduction of 
absorbable micellar cholesterol in duodenal aspirates [7]. Even if phytosterols have a primary mechanism 
of action in the intestine, their effects cause indirect changes in circulating LDL cholesterol. Reduced 
transportation of absorbed cholesterol to the liver results in increased tissue LDL receptors [8]. Further 
evidence of relative cholesterol deficiency after phytosterol treatment is the measured increase in whole 
body cholesterol biosynthesis of 38–53% [9]. These results also demonstrates the rationale for using 
phytosterols with statin drugs. 
Then, phytosterols are recognized as an important component of healthy diets and diets designed to 
reduce hypercholesterolemia. The United States National Cholesterol Education Program recommends 
dietary phytosterol supplementation of 2 g/day as a lifestyle modification for cholesterol reduction. 
 
Antioxidant and anti-inflammatory activity 
Reactive oxygen species (ROS) produced by stressed cells can damage DNA. Vivancos [10] reported that β-
sitosterol increases the activities of antioxidant enzymes, superoxide dismutase and glutathione peroxidase 
in cultured macrophage cells with oxidative stress induced by phorbol 12-myristate 13-acetate, indicating 
that phytosterols can protect cells from ROS damage. In another study [11], cultured lipopolysaccharide-
activated macrophage cells were treated with β-sitosterol and campesterol: the results showed a 
decreased production of prostaglandin E and prostaglandin I of series 2, by 68% and 67% (for sitosterol), 
and by 55% and 52% (for campesterol), respectively. These studies suggest that phytosterols are able to 
counteract the oxidative and inflammatory processes. 
 
Anticancerogenic activity 
Phytosterols seem to inhibit the development of various cancers mainly by inhibiting growth and promoting 
apoptosis of cancer cells by the activation of caspase enzymes. The increased activity of caspase enzymes 
could be attributed to the incorporation of phytosterols into cell membranes, which results in changes in 
membrane structure and function; furthermore, these changes increase the activities of proteins involved 
in extra- and intracellular signal-transduction pathways that activate caspase enzymes. Phytosterols could 
also inhibit cancer development by lowering blood cholesterol, as high blood cholesterol levels, and hence 
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the concentration of cholesterol in lipid rafts of cell membranes, are associated with reduced apoptosis of 
cancer cells. This combined evidence strongly supports an anticarcinogenic action of phytosterols and 
hence advocates their dietary inclusion as an important strategy in prevention and treatment of cancer 
[12]. 
 
1.1.2 - METABOLISM AND BIOAVAILABILITY  
After ingestion, phytosterols, like cholesterol and other lipids, are emulsified by bile salts secreted into the 
small intestine to form micelles for digestion. After micelle formation, the esterified phytosterols are 
hydrolyzed to free phytosterols probably by cholesterol esterase and pancreatic lipase [13]. Free 
phytosterols are then absorbed into enterocytes by ATP-binding cassette transporters which are also 
involved in cholesterol absorption. In the enterocytes these compounds are esterified with fatty acids by 
acyl-CoA cholesterol acyltransferases, and combined with cholesterol, triacylglycerol and apolipoproteins to 
form chylomicrons [14]. The chylomicrons are secreted into the lymph and then transferred to the 
bloodstream, where they are transformed to chylomicron remnants after the uptake of triacylglycerol by 
cells, and transported to the liver. In the liver, the phytosterols may either be used for synthesis of bile salts 
or be incorporated into very low-density lipoproteins and be secreted into the blood, from where they are 
converted to low-density lipoproteins and presented to cells for uptake [15]. In the tissues, phytosterols are 
incorporated into the cell membranes [16] and have been found to be highly concentrated in the lungs, 
adrenal cortex, intestinal epithelia and ovaries [17]. Phytosterols that are either not taken up by cells or 
secreted back into the blood are transported to the liver, from where they are excreted into the bile. 
 
 
 
 
1.2-RESVERATROL 
 
Resveratrol is a polyphenolic phytoalexin which is present in grapes, grape juice, red wine and other plant 
extracts [18]. In the grape species, this polyphenol reaches concentrations of 50-400 µg/g of fresh weight in 
the leaves. Fresh grape skin contains about 50-100 µg of resveratrol for gram [19]. Consequently, the 
amount of this compound varies considerably in different types of grape juice and wine depending on the 
grape variety, environmental factors in the vineyard, juice extraction and wine processing techniques. In 
grapes and wine, resveratrol occurs both as free form and resveratrol 3β-glucoside [20]. In red wine the 
concentration of resveratrol is in the range of 1.5-3 mg/L [21]. 
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This phytoalexin, produced in response to environmental stress or pathogenic attack, is an antifungal 
conferring  disease resistance in plant kingdom [22]. It is a hydroxyl substituted stilbene (fig.2). 
 
 
 
 
 
Figure 2. 
 
Resveratrol exists as trans and cis isomers. In the Vitaceae fungal infection or UV light stimulates the 
production of stilbene synthase and catalyzes the reaction of 4-hydroxycinnamoyl-CoA and malonyl-CoA to 
produce trans-resveratrol. In the grape berry, trans-resveratrol production is stimulated by UV light 
exposure, fungal infection, or injury [23]. In red wine a small amount of cis isomer has been detected and it 
is supposed that the cis form is derived by isomerization from the trans isomer during the fermentation of 
grapes [24]. The balance between trans and cis isomer is obtained after exposure to the daylight and more 
than half of the trans isoform may change to its cis isomer. Although both cis and trans forms exhibit 
anticancer activity [25], it is not clear whether the pharmacokinetic properties of the cis isomer are 
identical to those of the trans . 
Resveratrol is characterized by a number of bioactivities, such as antioxidant, anti-inflammatory, antitumor, 
cardioprotective, neuroprotective and immunomodulatory; it has been also recognized to have a delaying 
effect on aging. 
 
1.1.1 - BIOLOGICAL ACTIVITIES 
Antioxidant activity 
The antioxidant activities of polyphenols are due to the ability of the hydrogen of phenolic compounds to 
be donated, to neutralize free radicals produced by oxidative processes such as phospholipid peroxidation 
via UV radiation or by biologically-mediated events. It has been demonstrated that resveratrol may serve 
both as a primary antioxidant (free radical scavenger), which can directly react with free radicals and 
convert them into less active products [26,27], and as a secondary (preventive) antioxidant, which can 
lower the rate of oxidation by inhibiting enzyme activities. For example, resveratrol has been shown to 
inhibit the activities of cyclooxygenase, lipooxygenase and xanthine oxidase where increased levels of these 
enzymes lead to variety of diseases [28] such as cancer, arteriosclerosis or heart ischemia.  
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Cardiovascular activity 
Coronary artery disease remains the most deadly illness in western countries. Atherosclerosis, 
hypertension, obesity, endothelial dysfunction, alteration in platelet function and oxidative stress all 
contribute to the onset and progression of coronary artery disease. Many of the risk factors for this 
pathology such as age, sex and family history are uncontrollable; hence, emphasis must be placed on the 
modifiable risk factors. In particular, interest in dietary modification and even supplementation is at an all-
time high: examples of compounds that can be supplemented are omega-3 fatty acids, natural antioxidants 
and plant sterols, all recognized as “heart-healthy” foods [29]. Red wine was found to be one of these 
heart-healthy foods. In fact, the term “French paradox” refers to the observation that mortality due to 
coronary diseases in France, where red wine consumption is considerable, is significantly lower compared 
to that in other countries despite similarities in other risk factors such as dietary fat intake, obesity and 
cigarette smoking: resveratrol contributes to the antioxidant potential of red wine, and may be related with 
the decrease in coronary heart disease among wine drinkers. 
 
Atherosclerosis lies at the root of coronary artery disease. The generation of atherosclerotic plaque can be 
thought of as a stepwise process, initiated by the concentration-dependent transport of LDLs into the 
arterial wall followed by modification of lipids and proteins by oxidation and inflammation invasion of 
magrophages and their transformation into foam cells, which infiltrate smooth muscle cells with 
subsequent production of fibrin and extracellular matrix [30]. Resveratrol has been shown to attenuate 
each of these processes. 
 
LDL and HDL play quite different roles in the genesis of atherosclerosis. LDL is the cholesterol compound 
that is responsible for mural deposition and initiating atherosclerotic lesion, whereas HDL transports 
cholesterol back to the liver where it is metabolized. Treatment with resveratrol has been shown 
repeatedly to produce an anti-atherogenic serum lipid profile. It had been demonstrated that 
apolipoprotein E-deficient mice treated with daily oral resveratrol for 20 weeks had significantly lower 
circulating LDL and higher HDL compared to untreated controls [31]. Moreover, most studies show that this 
compound, administered at a wide range of doses and for even short periods of time, exerts a favorable 
effect on lipids profile in hypercholesterolemic animals. One possible explanation for this beneficial effect 
of resveratrol on lipids was proposed by Cho et al [32], who showed that HGM-CoA mRNA was up-
regulated by resveratrol supplementation in hamsters fed with a high-fat diet.  
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Intramural lipid accumulation is followed by LDL oxidation, which promotes macrophage migration into the 
vessel wall. Macrophages in turn take up oxidized LDL in large quantities and transform it into the 
cholesterol-rich foam cells, that characterize early atherosclerotic lesion [33]. Resveratrol by scavenging 
free radicals, decreases the oxidation of LDL and increases serum HDL, which not only has antioxidant 
activity but also promotes the excretion of excess cholesterol from macrophages, transporting it back to 
the liver [34]. Resveratrol has also been shown to inhibit monocyte recruitment and macrophage 
activation. Studies by Deng et al. [35] showed that this compound inhibits tumor necrosis factor-α (TNF-α)-
mediated adhesion of monocytes to endothelial cells and reduces protein and gene expression of the 
intercellular adhesion molecule 1 (ICAM-1) and vascular cell adhesion molecule 1 (VCAM-1), by inhibiting 
activation of NF-kB; ICAM-1 and VCAM-1 are essential to the localization of monocytes to early 
atherosclerotic lesion. Other studies also demonstrated that resveratrol down-regulates the production of 
other cytokines that contribute to the inflammatory environment, that is essential for the progression of 
atherosclerosis [36].  
 
Later in the course of atherosclerosis, smooth muscle cells, lured by the cytokines and growth factors 
secreted by macrophages, migrate into the atherosclerotic plaque, proliferate, and begin to secrete 
components of extracellular matrix, maturing the plaque into a capped, fibrous lesion. This process is 
mediated by various chemotactic factor proteins and receptors, and resveratrol may oppose multiple steps 
in this process. In fact, the estrogen receptor has also been shown to play a role in smooth muscle cells 
proliferation, and resveratrol has been found to modulate this receptor, leading to increased inducible 
nitric oxide synthase activity and subsequent decrease in smooth muscle cell proliferation [37]. 
 
The fibrotic plaque formed by migrating smooth muscle cells predisposes to the final step in 
atherosclerosis, which is thrombogenesis. Several hypotheses have been proposed to explain the inhibitory 
effect of resveratrol on platelet activation. The initial step in platelet activation is adhesion to type I 
collagen. Resveratrol decreased adhesion to collagen and fibrinogen after activation with 
lipopolysaccharide or thrombin [38]. Moreover, the protein kinase C (PKC) plays a key role in platelet 
activation, and resveratrol has been shown to depress the activity of PKC in platelet membranes [39]. Each 
of these mechanisms may contribute to the antithrombotic action of resveratrol. 
 
Antitumor activity 
Recent studies have documented that resveratrol has cancer-preventive properties [40], and this 
compound is currently at the stage of preclinical studies for human cancer prevention [41]. Its potential 
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chemopreventive and chemotherapeutic activities have been demonstrated at all three steps of 
carcinogenesis : initiation, promotion, progression.  
Both its m-hydroxyquinone and 4-hydroxylstyryl moieties have been shown to be important for 
determination of resveratrol inhibitory properties against various enzymes: these include lipoxygenases 
and cyclooxygeneses that synthesize pro-inflammatory mediators from arachidonic acid, protein kinases 
(PKCs and PKD), and receptor tyrosine kinases [42]. Resveratrol in addition regulates apoptosis and cell 
proliferation: it induces growth arrest followed by apoptotic cell death and interferes with cell survival by 
up-regulating the expression of pro-apoptotic genes while simultaneously down-regulates the expression of 
antiapoptotic genes [43].  
Resveratrol has been shown to be an effective chemopreventing agent in multiple murine models of human 
cancers. 
Skin cancer is the most common type of human malignancy. Topical administration of resveratrol has been 
tested for its efficacy against the development of several cutaneous disorders, including skin cancer. The 
chemoprotective effect of this compound was assessed on UVB-mediated skin tumorigenesis in the SKH-1 
hairless mouse model. Topical application of resveratrol either pre- or post-UVB significantly inhibited 
tumor incidence and delayed the onset of tumorigenesis [44] . 
 
Resveratrol is considered to be a phytoestrogen, given its structural similarity to diethylstilbestrol, a 
synthetic estrogen. It can bind to both alpha and beta estrogen receptors, and activates estrogen receptor-
dependent transcription in human breast cancer cells. Moreover, resveratrol inhibition of P450/Aromatase, 
by limiting the amount of available estrogens and consequently the activity of estrogen receptors, has been 
proposed to contribute to its activity against several types of cancer, including breast cancer . Despite a 
number of studies performed using both hormone-sensitive and hormone-resistant breast cancer cells, the 
estrogen modulatory effects of resveratrol remain controversial [45]. 
 
Furthermore, growth inhibitory effect of resveratrol has been demonstrated in various cultured prostate 
cancer cells, both hormone-sensitive and hormone-refractory, which mimic the initial or advanced stages of 
prostate carcinoma, respectively [46]. These studies have shown that resveratrol substantially modulates 
the growth of these cells and alters the expression of more than one set of functionally related molecular 
targets. In fact, this polyphenol can repress different classes of androgen-responsive genes, including 
prostate-specific antigen (PSA) [47].  
 
The primary etiological determinants for gastric cancer are thought to be exposure to chemical carcinogens 
and/ or chronic infection with Helicobacter pylori. Resveratrol was found to be effective in inhibiting the 
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replication of H. Pylori [48]: this provides a reason for the intervention studies using resveratrol to 
counteract gastric cancer [49]. 
A number of in vitro studies have also demonstrated the antiproliferative effect of resveratrol in various 
leukemic cell lines [50]. 
 
Anti-inflammatory activity  
One of the possible protective activities of antioxidants is the down-regulation of inflammatory responses, 
which includes inhibition of synthesis and release of pro-inflammatory mediators, modification of 
eicosanoid synthesis,  inhibition of enzymes such as ciclooxygenase-1 (COX-1) and ciclooxygenase-2 (COX-2) 
[51]. In mouse macrophages, resveratrol also has antioxidant activity, decreasing the production of reactive 
oxygen species (ROS) and reactive nitrogen species (RNS) and inhibiting nitric oxygen synthetase (NOS)-2 
and COX-2 synthesis as well as prostaglandin E2 production [52]. Furthermore, this compound inhibits the 
production of TNF-induced monocyte chemo-attractant protein which plays an essential role in early events 
during macrophage infiltration into adipose tissue, which results in chronic low-grade inflammation, a key 
feature of obesity in type 2 diabetes characterized by adipose tissue macrophage infiltration and abnormal 
cytokine production [53]. Finally, it is also established that some anti-inflammatory effects of resveratrol 
arise from its capability to up-regulate histone deacetylase sirtuin (SIRT1) activity, that also shows 
antitumor and anti-inflammatory effects [54]. Altogether, it is clear that key antitumor properties of 
resveratrol are linked to its anti-inflammatory effects. 
 
Resveratrol and SIRT-1  
The sirtuin family of proteins possesses NAD+-dependent deacetylase activity and/or ADP 
ribosyltransferase activity. The seven mammalian sirtuins (Sirt1–7) are localized differently within the cell 
and have a variety of functions [55]. Sirt1 is the most extensively studied member of the family and 
regulates diverse biological processes ranging from cell proliferation, differentiation and apoptosis, to 
metabolism [56]. 
In fact, SIRT-1 plays a context-dependent role in metabolic regulation, for instance by mediating effects in 
metabolic stress situations, such as high-fat-diet-induced obesity [57]. Furthermore, it confers protection 
against aging-associated metabolic diseases such as glucose intolerance and cancer. In light of the growing 
number of patients suffering from metabolic diseases, compounds that activate SIRT-1 directly or indirectly 
might offer protection against the onset of metabolic damage and promote healthy aging. 
Resveratrol was identified as the most potent activator of SIRT-1 [58]. Recently, however, it was shown that 
resveratrol may not activate SIRT-1 directly, but rather exerts its effects on SIRT-1 through activation of 
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AMPK, although additional direct SIRT-1 activation is not completely excluded [59]. Resveratrol treatment 
in mice fed a high-calorie diet consistently improved various health parameters, including glucose 
homeostasis, endurance, and survival [57] and it has therefore been suggested to act as a calorie restriction 
mimetic. In Timmers et al. study [60] a dietary supplementation of trans-resveratrol was given to obese 
volunteers over 30 days. Whole-body energy expenditure, mitochondrial function and other parameter 
have been examined: the results showed that resveratrol supplementation lowers energy expenditure and 
improves metabolic profile as well as general health parameters.  
 
Anti-diabetes activity 
Diabetes mellitus is a complex metabolic disease and is divided into different types: type 1 and type 2 
diabetes. Type 1 diabetes results from the autoimmune destruction of β cells and patients with this kind of 
diabetes are dependent on exogenous insulin. Type 2 diabetes is characterized by defects in insulin 
secretion and action. 
In the last few years, rodent studies and experiments in vitro provided evidences that resveratrol may be 
helpful in preventing and treating some metabolic diseases, including diabetes [61]. In general, the 
management of diabetes involves in three main aspects: reduction of blood glucose, preservation of β cells, 
and, in the case of type 2 diabetes, improvement in insulin action. Data in literature indicate that the 
beneficial effects of resveratrol in relation to this pathology comprise all of these aspects. 
The maintenance of blood glucose in the physiological range is pivotal in diabetes, since increased glycemia 
causes numerous diabetic complications. The anti-hyperglycemic effect of resveratrol observed in diabetes 
animals is thought to result from its stimulatory action on intracellular glucose transport. Increased glucose 
uptake by different cells isolated from diabetic rats was found in the presence of resveratrol. Interestingly, 
in experiments on isolated cells, resveratrol was able to stimulate glucose uptake in absence of insulin [62]. 
The stimulation of glucose uptake induced by resveratrol seems to be due to increased action of glucose 
transporter in the plasma membrane (GLUT4) [63]. 
Type 2 diabetes develops slowly and is usually accompanied by insulin resistance. Initially, blood glucose is 
maintained in the physiological range because of the compensatory increase in insulin secretion. This 
compensatory mechanism impedes and delays the diagnosis of diabetes. Moreover, chronic 
overstimulation of β cells causes their exhaustion and degradation, leading over time to insufficient 
secretion of insulin [64]. In animals with hyperinsulinemia, resveratrol was established to effectively reduce 
blood insulin and this inhibition was found to result from metabolic changes in β cells [65].  
Since chronic overstimulation of β cells is known to induce their degradation, inhibition of insulin secretion 
by resveratrol may attenuate these unfavorable effects.  
12 
 
The protective action of this polyphenol on the endocrine pancreas may also involve other mechanisms. 
One of them is the inhibitory influence of resveratrol on cytokine action. Studies in vitro and in vivo 
confirmed the important role of the inhibition of cytokine action in the mechanism activated by resveratrol 
in order to protects pancreatic β cells [66].  
Moreover, animal studies provided evidence that resveratrol may be useful to improve insulin action in 
type 2 diabetes. The improvement in insulin action caused by resveratrol seems to result from different 
effects. One of them is reduced adiposity. Resveratrol-induced reduction in body fat content was 
demonstrated in mice and rats on a hypercaloric diet [67]. Moreover, resveratrol ingestion was found to 
cause effects that are similar to those induced by calorie reduction [68]. Consistent with animal studies, 
experiments in vitro revealed reduced ATP content and decreased accumulation of triglycerides in isolated 
rat adipocytes exposed to resveratrol [69]. 
In conclusion, the preventive and therapeutic action of this compound in relation to diabetes is complex 
and involves in different effects. Elucidation of these beneficial properties of resveratrol is necessary to 
enable clinical human studies. 
 
Resveratrol and skin  
UV radiation, in particular UVB, is known to elicit a variety of adverse effects, such as erythema, sunburn, 
inflammation, hyperplasia, hyperpigmentation, immunosuppression, premature skin aging, and 
photocarcinogenesis [70]. UVB exposure is known to cause excessive generation of ROS, which if remains 
uncounteracted creates a situation of oxidative stress in the skin[71]. Topical application of resveratrol to 
SKH-1 hairless mice was found to inhibit UVB-mediated:  skin edema, inflammation, cyclooxygenase (COX), 
and ornithine decarboxyase (ODC), enzyme activity, ODC protein expression, lipid peroxidation and 
generation of hydrogen peroxide (H2O2) [72]. 
UV radiation is also known to cause significant leukocyte infiltration, which may be responsible for an 
additional outburst of ROS in the system. Some data demonstrated that resveratrol significantly inhibits 
UVB-mediated infiltration of leucocytes, suggesting the photochemopreventive potential of this compound 
and indicating that the antioxidant property may be responsible for the biological effects of resveratrol. 
 
Antiviral activity 
Resveratrol has been shown to be a potent antiviral molecule against various types of DNA and RNA 
viruses. However, even if the antiviral activity of resveratrol is becoming evident, the cellular pathways that 
lead to its protective activity are still far from being elucidated. Interestingly, some of the molecular 
pathways regulated by resveratrol such as p53, NF-κB or PML (promyelocytic leukemia protein) are also 
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main players in the control of virus infection. In addition, the activation of SIRT1 by resveratrol considered 
to be one of the main mediators of its activity, may also contribute to this regulation [73]. Further studies 
are required to clarify the contribution of SIRT1 in the regulation of the mentioned molecular pathways 
activated by resveratrol and their roles in the control of virus infection.  
The activity of resveratrol in protection from viral infection and putative molecular mechanisms that 
mediate its activity are summarized in Table 1 [73]. 
 
Virus Effect of resveratrol treatment Possible mechanism of action of resveratrol 
HSV-1, HSV-2 Inhibition of virus replication in 
vitro and in vivo 
Suppression of the NF-κB pathway activation  
VZV Inhibition of VZV replication in vitro  
HCMV Inhibition of HCMV replication in 
vitro 
Inhibition of the virus -induced EGFR 
activation 
EBV Inhibition of EBV early antigen 
induction in vitro 
 
HIV-1 I) Activation of the lytic cycle of 
HIV-   1 in vitro 
II) inhibition of HIV-1 replication 
when used synergistically with 
nucleoside analogues in vitro 
III) attenuation of the Tat-induced 
HIV-1 LTR transactivation in vitro 
 
I) activation of EGR-1 
II) prolongation of the S-phase of the cell cycle  
III) SIRT1 activation 
 
Influenza A 
virus 
Inhibition of influenza A virus 
replication in vitro and in vivo 
Inhibition of the protein kinase C activity  
Polyomavirus  Inhibition Polyoma DNA synthesis 
in vitro 
 
Table 1. Modulation of virus replication by resveratrol. 
 
1.2.2 - METABOLISM AND BIOAVAILABILITY  
Resveratrol is rapidly absorbed and metabolized, mainly as sulfo- and glucuro- conjugates which are 
excreted in urine. This high metabolic rate probably allows the transport, the distribution and the excretion 
of resveratrol. In rodents, the gut epithelium has been shown to be highly implicated in the metabolic 
14 
 
process, resulting in polar resveratrol metabolism products which then need specific transporters to cross 
cell membranes [74].  
In a study by Walle et al. [75], 
14
C-labeled resveratrol has been administered both orally and intravenously. 
Measurement of total radioactivity demonstrated high absorption after oral intake of resveratrol, without 
distinguishing resveratrol from its metabolites. The maximum plasma concentration was observed 1 h after 
oral intake and a second peak was present after 6 h, probably as a result of enteric recirculation of 
conjugate metabolites following reabsorption after intestinal hydrolysis. There was no second peak in any 
subject after the intravenous administration, showing no enterohepatic cycle. 
 
 
 
1.3 - QUERCETIN 
 
Quercetin (Fig. 3) is categorized as a flavonol one of the six subclasses of flavonoid compounds (Table 2). 
Flavonoids are a family of plant compounds that share a similar flavones backbone ( a three-ringed 
molecule with hydroxyl [OH] groups attached).a multitude of other substitutions can occur, giving rise to 
the subclasses of flavonoids and the different compounds found within these subclasses. 
 
 
 
 
 
 
 
Figure 3. 
 
Subclass Select Example 
Flavones Apigenin, Luteolin 
Flavonols Quercetin, Kaempferol 
Flavanones Hesperidin, Narigenin 
Flavanols (also called catechins) Epicatechin, Gallocatechin 
Anthocyanidins Cyanidin, Malvidin 
Isoflavones Genistein, Daidzein 
Table 2. Flavonoid subclasses and examples. 
HO
OH
O
O
OH
OH
OH
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Flavonoids also occur as either glycosides (with attached sugar) or as aglicones (without attached sugars) 
[76]. Quercetin glucosides are found in a variety of foods including apples, berries, grapes, onion, shallots, 
tea and tomatoes. the aglycone form of quercetin is found in much lesser amounts in diet. Two of the 
better food sources are onion and shallots, but depending upon which part of these foods is eaten. For 
example, quercetin in shallots flesh is about 99.2 % quercetin glucosides and 0.8 % quercetin aglycone. In 
dry shallot skin the composition is almost the opposite 83,3% quercetin aglycone and 16.7% quercetin 
glucoside [77]. Similar differences exist with onions. The flesh of onions contains mostly quercetin 
glucosides, with only trace amounts of quercetin aglycone. Like shallots, the skin and outermost layers of 
an onion have much more quercetin aglycone [78]. Growing conditions might significantly influence the 
amount of quercetin in food, with evidence indicating that organically grown tomatoes have significantly 
higher quercetin aglycone content than conventionally produced tomatoes. 
 
1.3.1 - BIOLOGICAL ACTIVITY 
Antioxidant activity 
Quercetin has been shown to be an excellent in vitro antiossidant. Within the flavonoid family, quercetin is 
the most potent scavenger of ROS, including O2
.-
 and RNS like NO
.
 and ONOO
-
[79]. These antioxidant 
capacities of this compound are attributed to the presence of two antioxidant pharmacophores, cathecol 
group and OH group in position 3, within the molecule that have the optimal configuration for free radical 
scavenging [80]. In fact, when quercetin reacts with a free radical, it donates a proton and becomes a 
radical itself, but the resulting unpaired electron is localized by resonance, making the quercetin radical too 
low in energy to be reactive [81]. 
Quercetin can also protect against the more obvious environmental causes of free radicals, such as 
smoking. Cigarette tar is a source of free radicals, which have been found to damage erythrocyte 
membranes. Begum and Terao [82] found that the quercetin aglycone and its conjugate metabolites 
(quercetin-3-O-β-glucuronide and quercetin-3-O-β-glucoside) could protect erythrocytes from the 
membrane damage that is caused by smoking. 
New evidence supports that quercetin not only has antioxidant capabilities but more importantly may act 
as a signaling molecule. In fact, it has been shown that this compound can act as antioxidant leading to the 
formation of quinones and prooxidants [83-84]. Furthermore, quercetin can be metabolized to 
quinone/quinone methide metabolite such as o-semiquinone and o-quinone. O-semiquinone has the 
capability to generate O2
- 
in cell culture whereas o-quinone depletes glutathione (GSH) in the presence of 
excess ascorbate [85-86]. The depletion of GSH and generation of O2
- 
 through these quercetin metabolites 
suggest a prooxidant effect. The formation of quinone/quinone methide metabolites may lead to a low 
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level production of oxidants, which may in turn activate certain signaling cascades. By acting as a sensor as 
well as a signaling molecule, H2O2 is an important regulator of signal transduction. An additional mechanism 
of action of quercetin then is through regulating H2O2 levels: H2O2 regulates endothelial cell function such 
as proliferation, inflammatory responses, apoptosis, and endothelium-dependent vasorelaxation [87]. 
 
Anti-inflammatory activity 
Quercetin is known to possess strong anti-inflammatory capacities. Several in vitro studies have shown that 
flavonoids are capable of inhibiting LPS-induced cytokine production. For instance, quercetin inhibits LPS-
induced TNFα production in macrophages and LPS-induced IL-8 production in lung cell [88].  
A possible explanation for these anti-inflammatory effects of quercetin may be found in the interplay 
between oxidative stress and inflammation: ROS are not only involved in the occurrence of oxidative stress, 
but also in the promotion of inflammatory processes via activation of transcription factors such as NF-κB 
and activator proteins (AP)-1 which induce the production of cytokines like TNFα [89]. Consequently, 
scavenging ROS would not only prevent the occurrence of oxidative stress but also help mitigate 
inflammation.  
In addition quercetin, in according with several other in vitro studies, inhibits the production of 
inflammation-production enzymes (cyclooxygenase and lipoxygenase) [90], NO production and nitric oxide 
synthase (NOS) expression [91]. 
 
Cardiovascular activity 
Consumption of flavonoids found in fruits, vegetables, and beverages such as tea and wine are inversely 
correlated with mortality from coronary heart disease. The several studies demonstrated an inverse 
relationship between flavonoid intake and occurrence of myocardial infarction [92]. The cardiovascular 
benefits of flavonoid-rich foods have been attributed to their antioxidant effects (inhibiting the oxidation of 
low density lipoproteins (LDL) [93]), NO mediated vasodilatory effects, reducing platelet aggregation [94], 
and activating Nrf2-induced phase II detoxification through antioxidant response element (ARE)-mediated 
gene expression [95]. Quercetin is the most prevalent flavonoid in the human diet and it has been shown to 
engage in redox cycling reactions in cellular system thereby endowing both antioxidant and prooxidant (by 
generating H2O2) properties [96-97]. The effect of quercetin on vessel function are not clear and especially 
whether the proposed generation of H2O2 can modulated eNOS activity and vessel relaxation. In fact, 
vascular endothelial cells have the capacity to release H2O2 and endothelium-derived H2O2 stimulates 
EDHF. The endothelium produces and releases several vasoactive mediators involved in vessel tone, such as 
NO, prostacyclins, and EDHF. 
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Moreover, quercetin, in human, inhibits platelet aggregation and thrombus formation [98]. Quercetin 
appears to be effective in improving blood pressure and might have an effect on cholesterol in human. 
 
Antitumor activity 
Apart from scavenging ROS, another important effect of quercetin is to regulate cell cycle by modulating 
several molecular targets, including p21, cyclin B, p27, cyclin-dependent kinases and topoisomerase II, even 
if the mechanisms involved have not been elucidated yet. Depending on the cell type and tumor origin, 
quercetin is able to block the cell cycle at G2/M or at the G1/S transition. In particular, quercetin causes 
G2/M arrest in human esophageal squamous cell carcinoma cell line through up-regulation of p73 and 
p21waf1 and subsequent down-regulation of cyclin B1, both at the mRNA and protein levels [99].In human 
breast carcinoma cell lines low doses of quercetin inhibit proliferation. Cell-cycle arrest occurs at the G1 
phase through the induction of p21 and through the concomitant decrease of phosphorylation of the 
retinoblastoma protein (pRb) [100].In the same cell model, quercetin downregulates the cyclin B1 and 
cyclin-dependent kinase (CDK) 1, which are essential in the progression to the G2/M phases of the cell cycle 
[101]. Similarly, in the human lung cancer cells, quercetin glucuronides induce cell-cycle arrest at G2/M 
phase by increasing the expressions of proteins such as cyclin B [102]. A similar antiproliferative effect has 
also been observed both for highly or moderately aggressive prostate cancer cell lines, whereas no effect 
has been found for poorly aggressive prostate cancer cells [103].  
In add, quercetin has shown a pro-apoptotic activity. The capability of quercetin to induce apoptosis in 
cancer cells (via both the intrinsic and extrinsic pathways) undoubtedly renders this molecule an interesting 
tool in the oncology field. The pro-apoptotic effects of quercetin may result from multiple pathways. First, 
in several kind of cell lines, quercetin treatment increases cytosolic Ca
2+
 levels and reduces the 
mitochondrial membrane potential (MMP), thus promoting activation of caspase-3, -8 and -9 [104]. 
Second, quercetin is a potent enhancer of TNF-related [105]. Third, the anti-proliferative and pro-apoptotic 
effects could be related to the capability of quercetin to directly bind tubulin, provoking the 
depolymerization of cellular microtubules [106]. 
Several studies have investigated the role of p53 in the antiproliferative and proapoptotic action of 
quercetin on tumor cell lines. In fact, quercetin causes cell-cycle arrest and apoptosis by inducing p53 
phosphorylation and by stabilizing p53 both at the mRNA and protein level [107]. The presence of p53 
limits the effect of quercetin, since when p53 is inhibited, cells become more sensitive to quercetin related 
cytotoxicity and quercetin-related apoptosis. The effect of the presence or absence of p53 on quercetin 
induced cytotoxicity and apoptosis is consistent with the involvement of this polyphenol in the oxidative 
cell balance. 
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The studies of quercetin on cellular models offer an almost exhaustive explanation of the mechanisms that 
link this compound to the oxidative cell balance and to the control of cell-cycle phases; these results invite 
major attention to study quercetin in more complex and sophisticated animal models. 
 
Allergy, Asthma, and Atopic Disease 
In vitro quercetin inhibits histamine release by mast cells and basophils [108] suggesting an antiallergy 
effect. Animal evidence indicates that quercetin might have therapeutic potential for allergic airway 
disease. Several studies conducted in guinea pigs have reported that quercetin, provided orally or 
administered via inhalation, has anti-asthmatic activity [109]. In murine models of allergic airway 
inflammation and asthma, quercetin had pronounced anti-inflammatory effects [110], reduced eosinophil 
and neutrophil counts and infiltration in in lung tissue, and inhibited asthmatic reactions [111].  
In addition, quercetin inhibits anaphylactic contraction of giunea pig ileum smooth muscle in vitro [112]. 
Human epidemiological research reports an inverse association between intakes of quercetin and asthma 
incidence [113]. Human intervention studies investigating quercetin for asthma and atopic disease are 
currently lacking. However, two studies have investigated the effects of an enzymatically-modified 
isoquercitrin (a quercetin glycoside) on allergic symptoms. In these studies, this specific quercetin glycoside 
provided a statistically significant relief of ocular symptoms, but no statistically significant relief of nasal 
symptoms caused by pollen [114]. 
In addition, other studies reported that quercetin might reduce erythema and burning sensation. 
Presumably this occurred in part because quercetin inhibited niacin-induced human mast cell prostaglandin 
D2 release [115].  
 
Antiviral and antibacterial activity 
Quercetin has in vitro antiviral activity against reverse transcriptase of HIV and other retroviruses like 
Herpes simplex virus type 1, polio-virus type 1, respiratory syncytial virus (RSV) [116], and hepatitis C [117]. 
Quercetin has in vitro antibacterial activity against five microorganisms (Actinobacillus 
actinomycetemcomitans, Actinomyces viscosus, Porphyromonas gingivalis, Fusobacterium nucleatum, and 
Actinomyces naeslundii) associated with onset and progression of periodontal disease [118]. It also has in 
vitro and in vivo activity against H. pylori [119].  
Quercetin exerts immune and inflammation modulating activity in several murine models of autoimmunity. 
For example, in experimental allergic encephalomyelitis a T-helper 1 (Th1) cell-mediated inflammatory 
demyelinating autoimmune disease model of multiple sclerosis, quercetin ameliorated this patology  by 
blocking IL-12 signaling and Th1 differentiation [120]. 
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Skin and quercetin 
As mentioned above, quercetin has the highest antiradical activity compared to other flavonoids and its 
properties include ROS scavenging, inhibition of peroxidation and metal ions chelation. These evidences 
suggest the possible effectiveness of quercetin topical administration to prevent UVB radiation-induced 
skin damage [121]. Acute UV skin exposure induces an immediate inflammatory response with erythema 
and leukocyte infiltration. It has been suggested that the modulation of redox-sensitive transcription 
factors such as nuclear factor (NF)-κB by ROS is a central and early event in the induction of inflammatory 
reactions [122]. The NF-κB is an oxidative stress sensitive factor that activates multiple target genes 
involved in the expression of several pro-inflammatory mediators. In agreement with the inflammatory 
character of the UVB irradiation, it induces a dose-dependent increase in myeloperoxidase (MPO) activity 
[123]. The topical application of a formulation containing quercetin significantly decreased the UVB-
induced increase of MPO in the skin [124]. 
The antioxidants are mainly concentrated in the epidermis compared to the dermis; in fact, the UVB 
radiation exposure induces a greater decrease in the epidermis antioxidant systems compared to the 
dermis [125]. Therefore, the epidermis can be considered the first line of skin defense and the glutathione 
redox status has been confirmed as an early and sensitive sensor of UVB-induced epidermal oxidative stress 
[126]. In fact, a dose-dependent depletion of GSH was detected in the skin after UVB irradiation. In 
Casagrande et al. study [127] it has been demonstrated that the topical treatment with a formulation 
containing quercetin significantly prevented the UVB irradiation-induced GSH depletion.  
During multiple intermittent UV exposure, repeated processes induce the formation of severely damaged 
collagen and ultimately skin wrinkling and reduced elasticity. The degradation of the extracellular matrix is 
a consequence of metalloproteinases activity in epidermal keratinocytes and fibroblasts. This process is 
followed by formation of imperfectly repaired collagen [128]. Furthermore, the UVB irradiation induction of 
proteinases expression in the epidermis has been recently demonstrated; it also induces gene transcription 
factors for metalloproteinases. The proteinases may be produced by a variety of cells including 
macrophages and neutrophils; Casagrande et al. study [127] also demonstrated that the formulations 
containing quercetin inhibited the proteinases secretion/activity in the skin. These evidences further 
strengthen the possible use of topical formulations containing quercetin to prevent UVB radiation skin 
damages.  
 
1.3.2 - METABOLISM AND BIOAVAILABILITY 
Quercetin is found in far greater amounts in the diet as glycosides than as quercetin aglycone. When 
quercetin glycosides are ingested, glycosyl groups can be released during chewing, digestion, and 
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absorption. As an example, enzymes in the mouth and intestine can hydrolyze quercetin glycosides to 
aglycones. [129]. Several human studies have been conducted to compare the bioavailability of quercetin 
aglycone and glycosides. A study of absorption in ileostomy patients revealed absorption of 24 % of the 
pure aglycone and 52 % of quercetin glycosides [130]. Other studies have confirmed that the absorpition of 
quercetin is considerably enhanced by its conjugation with a sugar group [131].  
After absorption, quercetin is metabolized in various organs, such as the small intestine, colon, liver and 
kidney [132]. Metabolites formed in the small intestine and liver are mainly the result of phase II 
metabolism by biotransformation enzymes and therefore include methylated, sulfated and glucuronidated 
forms [133]. Moreover, bacterial ring fission of the aglycone occurs both in the small intestine and in colon, 
resulting in breakdown of the backbone structure of quercetin and the subsequent formation of smaller 
phenolics [132]. Normally, human quercetin plasma concentration is in low nanomolar range, but upon 
quercetin supplementation it may increase to high nanomolar or low micromolar range [134]. A recent 
study regarding the tissue distribution in rats and pigs has shown that, upon quercetin supplementation, 
the highest accumulation of the flavonoid and its metabolites is found in lungs (rats) and liver and kidney 
(pigs) [135]. It has been shown that the half-lives of quercetin metabolites are rather high (from 11 to 28 h). 
This indicates that, upon repeated quercetin supplementation, they could attain a considerable plasma 
level and pharmacological function of dietary quercetin, including antioxidant activity, should be exerted 
exclusively by its conjugated metabolites [136]. 
 
 
 
 
1.4-FATTY ACIDS 
 
Fatty acids are classified as saturated fatty acid (SFA), monounsaturated fatty acid (MUPA), and 
polyunsaturated fatty acid (PUFA). Omega-3 (n-3), omega-6 (n-6), and omega-9 (n-9) unsaturated fatty acid 
structures are based on the position of the first double bond at the third, sixth or ninth position from the 
methyl (omega) terminal of the aliphatic carbon chain. 
Humans and other mammals can synthesize saturated fatty acids and some monounsaturated fatty acids 
from carbon groups in carbohydrates and proteins; they lack the enzymes necessary to insert a cis double 
bond at the n-6 or the n-3 position of a fatty acid [137]. Consequently, omega-6 and omega-3 fatty acids 
are essential nutrients. The parent fatty acid of the omega-6 series is linoleic acid (18:2n-6), and the parent 
fatty acid of the omega-3 series is linolenic acid (18:3n-3.). Humans can synthesize long-chain (20 carbons 
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or more) omega-6 fatty acids, such as dihomo-gamma-linolenic acid (DGLA; 20:3n-6) and arachidonic acid 
(AA; 20:4n-6) from linoleic acid and long-chain omega-3 fatty acids, such as eicosapentaenoic acid (EPA; 
20:5n-3) and docosahexaenoic acid (DHA; 22:6n-3) from linolenic acid through a series of desaturation 
(addition of a double bond) and elongation (addition of two carbon atoms) reactions. 
Unlike the linolenic and linoleic acid, oleic acid (18:1n-9), is consumed in substantial amounts in the typical 
Western diet and is not an essential fatty acid. There is little eicosatrienoic acid (ETA; 20:3n-9) in cell 
membranes, however, probably because of the overwhelming competition from dietary linoleic acid for the 
relevant desaturase and elongase enzymes. 
 
1.4.1 - PHARMACOLOGICAL ACTIVITIES 
Omega-6 and omega-3 PUFA are important structural components of cell membranes. When incorporated 
into phospholipids, they affect cell membrane properties such as fluidity, flexibility, permeability and the 
activity of membrane bound enzymes [138]. 
DHA is selectively incorporated into retinal cell membranes and postsynaptic neuronal cell membranes, 
suggesting it plays important roles in vision and nervous system function. DHA is found at very high 
concentrations in the cell membranes of the retina; the retina conserves and recycles DHA even when 
omega-3 fatty acid intake is low [139]. Animal studies indicate that DHA is required for the normal 
development and function of the retina. Moreover, these studies suggest that there is a critical period 
during retinal development when inadequate DHA will result in permanent abnormalities in retinal 
function. 
The phospholipids of the brain's gray matter contain high proportions of DHA and AA, suggesting they are 
important to central nervous system function [140]. Brain DHA content may be particularly important, 
since animal studies have shown that depletion of DHA in the brain can result in learning deficits. It is not 
clear how DHA affects brain function, but changes in DHA content of neuronal cell membranes could alter 
the function of ion channels or membrane-associated receptors, as well as the availability of 
neurotransmitters [141]. 
Eicosanoids, derived from 20-carbon PUFA, are potent chemical messengers that play critical roles in 
immune and inflammatory responses. During an inflammatory response, DGLA, AA, and EPA in cell 
membranes can be metabolized by enzymes known as cyclooxygenases and lipoxygenases to form 
prostaglandins and leukotrienes [142].  
AA is the progenitor of both PGE2 and LTB4 via the cyclooxygenase and 5-lipoxygenase enzymatic pathways, 
respectively. PGE2 and LTB4 have pro-inflammatory biological actions. PGE2 can cause pain and vasodilation 
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and LTB4 is a chemoattractant and activator of neutrophils; together they can cause vascular leakage and 
extravasation of fluid. 
EPA, the n-3 homologue of AA, can inhibit AA metabolism competitively via the cyclooxygenase and 5-
lipoxygenase enzymatic pathways and, thus, can suppress production of the n-6 eicosanoid inflammatory 
mediators. EPA is a potential cyclooxygenase substrate for the synthesis of PGE3, which also has 
inflammatory activity [143, 144]. EPA is also a 5-lipoxygenase substrate and can lead to the formation of 
LTB5, but LTB5 has little inflammatory activity compared with LTB4 [145]. 
In those who consume typical Western diets, the amount of AA in cell membranes is much greater than the 
amount of EPA, resulting in the formation of more eicosanoids derived from AA than EPA. However, 
increasing omega-3 fatty acid intake enhances the EPA content of cell membranes, resulting in higher 
proportions of eicosanoids derived from EPA [146].  
Many antiinflammatory pharmacotherapies are directed at inhibiting the production of these inflammatory 
mediators and thus possibilities exist for therapies that incorporate n-3 and n-9 dietary fatty acids. 
However, there are competitive interactions between dietary PUFAs; thus, in any examination of the 
effects of dietary n-3 or n-9 PUFAs, it is important to consider also the background dietary n-6 PUFAs. 
The results of epidemiological studies and randomized controlled trials suggest that replacing dietary SFAs 
with omega-6 and omega-3 PUFA lowers LDL cholesterol and decreases cardiovascular disease risk.  
A reduction in omega-6 fatty acids leads to skin lesions, anemia, increased platelet aggregation, 
thrombocytopenia, fatty liver, delayed wound healing, increased susceptibility to infections, diarrhea, 
growth delay in childhood. 
The lack of omega-3 fatty acids is characterized by neurological symptoms, reduced visual acuity, skin 
lesions, developmental delay, compromised learning ability, abnormal electroretinogram. 
Maintaining an optimal omega-3/omega-6 ratio is essential in the prevention of some pathologic conditions 
as well as in the therapy of diseases due to immuno-allergic causes and to lipid metabolism errors. In 
particular, a correct omega-3/omega-6 ratio is important: to prevent cardiovascular diseases and to control 
their risk factors [147, 148]; to prevent and treat skin and immuno-allergic affections [149]; in congenital 
metabolic pathologies, such as adreno-leukodystrophy and phenylketonuria.  
In addition, fatty acids are essential components of natural lipids, which determine the physiological 
structure and function of the human skin [150]. They are present in the epidermis, especially in the stratum 
corneum, the outermost layer, and cell membranes [151]. Many effects of fatty acids can be linked to 
changes in membrane lipid composition affecting cell signaling mechanisms originating from membranes 
[152]. Skin aging may influence epidermal lipids and free fatty acid composition, and their physiological 
functions may be involved in aging process. In fact, the levels of SFAs such as palmitic acid and stearic acid, 
23 
 
PUFAs such as linoleic acid and 11,14,17-eicosatrienoic acid , one of the omega-3 polyunsaturated acids, 
were decreased 
in aged skin by 15%, 31%, 7%, and 56%, compared with those in young skin, respectively [153].Moreovere, 
also photoaging process may affect the fatty acids composition in human skin [153]. 
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2 - AIM 
 
 
This PhD project aims to overcome the problems related to poor bioavailability of some natural 
polyphenols and sterols, through the synthesis of the corresponding esters with saturated and unsaturated 
fatty acids. 
The limitation of pharmaceutical, cosmetic and dietary application of polyphenols and sterols is due to their 
poor solubility and stability in lipophilic media: these features are also undermining their oral and dermal 
bioavailability. The synthesis of more lipophilic derivatives, especially esters, could lead to an increase in 
lipophilicity, and then in the bioavailability and permeability, in particular in the skin. 
The selected natural compounds have all proven biological activities and are widely described in literature. 
The choice of saturated and unsaturated fatty acids as acid components for the esterification is due to their 
beneficial activities: thus, the synthesis of such esters would introduce in a single molecule (prodrug) two 
moieties both pharmacologically active. 
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3 - MATERIALS AND METHODS 
 
 
3.1 - MATERIALS 
 
β-sitosterol (purity grade 60%), quercetin, oleic acid (purity grade 90%), linolenic acid (purity grade 70%), 
linoleic acid (purity grade 95%), palmitoyl chloride, stearoyl chloride were purchased from Sigma Aldrich 
(Milan, Italy); resveratrol was purchased from Polichimica (Bologna, Italy). All solvents, deuterated solvents, 
reagents and enzymes used were purchased from Sigma Aldrich.  
 
 
 
 
3.2 - METHODS 
 
3.2.1 - INFRARED SPECTROSCOPY ANALYSIS (FT-IR) 
Fourier Transform Infrared Spectroscopy (FT-IR) is an analytical technique used to identify functional 
groups in the examined molecules. 
Measurements have been performed by using a SPECTRUM ONE FT-IR spectrometer (Perkin Elmer). 
Spectra have been acquired by DATA MANAGER 2 software (Perkin Elmer). 
Sample preparation: 
Samples in solid form and samples in liquid/semi-solid form have been treated differently: 
• Solid form sample: 
The sample is mixed at a ratio of 1:100 w/w with potassium bromide and homogenized in an agate 
mortar; the powder is then pressed, without applying vacuum, under a 9 tons pressure for 4 
minutes, to form a thin tablet that is gently put on a suitable support for the analysis. The 
acquisition of spectra have been performed using the following parameters: 
Wavelenght:  4000 - 450 cm
-1
 
Resolution:  4 cm
-1
 
Scan repetitions:  8 
Background:  KBr tablet   
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• Liquid/semi-solid form sample: 
The substance is dropped between two sodium chloride windows. The acquisition of spectra have 
been performed using the following parameters: 
Wavelenght:  4000 - 600 cm
-1
 
Resolution:  4 cm
-1
 
Scan repetitions:  4 
Background:  NaCl window  
 
3.2.2 - NUCLEAR MAGNETIC RESONANCE ANALYSIS (NMR) 
NMR is a technique used to determine the structure of the investigated compounds. 
NMR spectra have been registered, depending on different needs, by using two different instruments: 
• Varian Mercury Plus 200, operating at 200 MHz, coupled with Sun software 
• Bruker Advance 500, operating at 500 MHz, coupled with Bruker X-Win NMR 3.0 software. 
Sample preparation: 
8-10 mg  (
1
H-NMR) or 50 mg (
13
C-NMR) of substance have been dissolved in chloroform (CDCl3) or dimethyl 
sulfoxide (DMSO) depending on their solubility.   
 
3.2.3 - ULTRAVIOLET-VISIBLE SPECTROSCOPY ANALYSIS (UV-Vis) 
UV-vis allow the determination of the maximum absorption wavelength of the analyzed molecule. This 
value helps the identification of the analytes. Measurement have been performed by using a Jasco V-530 
UV-vis spectrophotometer in different wavelength ranges, depending on the solvent:    
• Methanol: 210-600 nm  
• Chloroform: 235-600nm  
Sample preparation: 
Weighted quantities of the samples have been dissolved in the appropriate solvent (methanol or 
chloroform) and spectra have been registered using quartz cuvettes. Solvent backgrounds have been 
subtracted.   
 
3.2.4 - HIGH PERFORMANCE LIQUID CHROMATOGRAPHY (HPLC) 
HPLC is a chromatographic technique which allows to separate two or more components in an analyte, 
based on differential affinity of the compounds for a stationary phase, placed inside the chromatographic 
column, and a mobile phase, flowing through it. The stationary phase and the mobile phase are chosen 
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according to the sample to be analyzed. Depending on the stationary phase used, HPLC analysis can be 
carried out in normal phase or reversed phase: 
 Normal phase: in this case the column inner packing is polar, commonly made of silica 
 Reversed phase: the column packing is apolar, commonly made of derivatized silica 
The choice of the mobile phase is closely related to the stationary phase employed: usually in normal phase 
HPLC apolar solvents are used, such as hexane and ter-butanol, whereas in reversed phase HPLC polar 
solvents such as methanol, acetonitrile and water are used.  In addition, HPLC can be performed using one 
or more mobile phases: if the composition of the mobile phase is constant,  the elution is performed in 
isocratic conditions, while if the composition of the mobile phase changes during the analysis the 
chromatographic separation is described as a gradient elution. 
The samples to be analyzed are dissolved in a suitable solvent, usually similar or identical to the mobile 
phase.   
After leaving the column, the mobile phase enters a detector, needed to provide qualitative and 
quantitative information on the analyte components. The most common detectors are based on UV-vis 
light absorption. DAD (Diode Array Detector) allows to record the absorbance spectrum of the analyte in a 
specified range of wavelenghts. 
β-sitosterol, resveratrol and their respective derivatives analyses were performed by using an HPLC system 
equipped with a quaternary pump Waters Delta Prep 600E, an injector Rheodyne 7125 with a 20 μl loop, a 
thermostat Column Block Heater Mod. 7940 Hichrom Ltd., a detector DAD 2996. The acquired data were 
processed by software Empawer 2. 
Quercetin and its derivatives were performed by using an HPLC system equipped with a quaternary pump 
Merck Hitachi L-7100, an injector Rheodyne 7125 with a 20 μl loop, a thermostat Column Block Heater 
Mod. 7940 Hichrom Ltd., a detector DAD Hewlett Packard HP 1050. The acquired data were processed by 
software HP CHEM. 
 
3.2.5 - MASS SPECTROMETRY (MS) 
All synthesized derivatives were analyzed by using a LCQ Advantage mass spectrometer, equipped with ion 
trap and ESI (Electrospray Ionization) source.  
 
3.2.6 - ANTIOXIDANT ACTIVITY 
In collaboration with Dr. Angela Maria Rizzo from Dept. “Scienze Molecolari Applicate ai Biosistemi”, 
Università degli Studi, Milan, the antioxidant activity of resveratrol and its tri-esters was tested using ABTS 
(2,2’-azinobis-[3-ethylbenzthiazoline-6-sulphonic acid]) and DPPH (1,1-diphenyl-2-picrylhydrazyl) assays. 
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TEAC (Trolox Equivalent Antioxidant Capacity) and IC50 values of the compounds were calculated and 
compared. 
 
ABTS assay 
The ABTS assay involves the oxidation of ABTS (2,2’-azinobis[3-ethylbenzothiazoline-6-sulphonate]) to a 
radical cation, ABTS
•+
. ABTS
•+
 is enzymatically pre-generated and the antioxidant or sample to be analyzed 
is added to the reaction mixture. This results in the disappearance of ABTS
•+
, which is measured by the 
decrease in absorbance; the ABTS radical cation has an absorption maximum at 735 nm.  
This method is based on the capacity of different components to scavenge ABTS radical cation compared to 
a standard antioxidant (Trolox, vitamin E analogue) in a dose-response curve. 
Stock solutions: 
• Solution 1: potassium persulfate (K2S2O8) 2.5 mM in water 
• Solution 2: ABTS 7.4 mM in water 
• Solution 3: obtained by mixing Solution 1 and Solution 2 in equal quantities and allowing them to 
react for 12 h at room temperature in the dark. 
• Solution 4: Trolox 1 mM in methanol, used to prepare standard solutions 
• Solution 5: obtained by dilution of 10 ml of Solution 3 to 100 ml of methanol (Abs735 = 
approximately  0.700) 
• Solution 6: sample solution 
Standard solutions preparation (Table 3) 
 
Standard solution Solution 4 vol. (μl) Solution 5 vol. (μl) Solvent vol. (μl) Trolox conc. (μM) 
1 0 950 50 0 
2 5 950 45 5 
3 10 950 40 10 
4 15 950 35 15 
5 20 950 30 20 
6 25 950 25 25 
7 30 950 20 30 
 
Table 3. 
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Results acquisition:  
• for each acquisition Solution 5, solvent and Solution 4 (in the prescribed order) were added in a 
cuvette, then the mixture was stirred and after 3 minutes its absorbance at 735 nm was acquired 
using a UV-vis spectrophotometer; 
• the calibration curve was plotted inserting the data in a graph (absorbance vs. Trolox 
concentration); 
• the samples were analyzed and the results were interpolated with the calibration curve and the 
TEAC (Trolox Equivalent Antioxidant Capacity) values were obtained. 
 
DPPH assay 
The DPPH assay makes use of a stable free radical DPPH• (1,1-diphenyl-2-picrylhydrazyl). The reaction 
involves a colour change from violet to yellow that can be easily monitored using a spectrophotomer at 520 
nm.  
DPPH solution preparation: prepared by dissolving 27 mg of DPPH with 25 ml of ethanol 70%, stirred until 
complete dissolution and then stored in the dark. 
Samples preparation: an increasing volume of analyte (50 µl by 50 µl) was added to different test tubes; 
ethanol 70% was added to a final volume of 1 ml and then 500 µl di DPPH was added. The mixture was 
stirred and stored for 30 minutes in the dark. 
Results acquisition: the samples were analyzed using an UV-vis spectrophotometer (520 nm), obtaining 
absorbance values relevant to the residual amounts of DPPH•: then IC50 value was obtained by 
interpolation, plotting a graph with the calculated residual amounts of DPPH• vs. sample concentration. 
IC50 value (µg/ml) represents the concentration of sample leading to a 50% decrease of DPPH•: the higher 
the IC50 value, the lower the antioxidant activity. 
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4 - EXPERIMENTAL PART 
 
4.1 - β-SITOSTEROL 
 
4.1.1 - CHEMICAL SYNTHESIS OF β-SITOSTEROL FATTY ESTERS 
β-sitosterol esters were obtained both with saturated (palmitic acid) and unsaturated (oleic and linolenic 
acid) fatty acids. 
 
 
 
 
R= R1CO- 
Scheme 1.  
Under nitrogen flow, β-sitosterol was dissolved in 20 ml anhydrous toluene and the solution was stirred at 
room temperature. Then dimethyl-aminopydirine (DMPA) was added and, using an ice bath, the 
temperature was decreased to 0°C; afterwards, the chloride was added dropwise. The obtained reaction 
mixture was carried to room temperature and magnetically stirred for 12 h, repairing from daylight. 
The mixture was washed with saturated NaHCO3 water solution and then with water (3 x 20 ml). The 
organic layer was dried over anhydrous Na2SO4 and evaporated under vacuum (77 mbar, 40 °C). 
When the acyl chloride was not commercially available, it  was prepared as follows: 
R1COOH     +   (COCl)2 
Scheme 2. 
The unsaturated fatty acid was dissolved in 20 ml anhydrous toluene and the solution was stirred at room 
temperature under anhydrous conditions. Then, using an ice bath, the temperature was decreased to 0 °C 
and oxalyl chloride was added dropwise. The reaction mixture was carried to room temperature and 
magnetically stirred for 3 h. The reaction was monitored using IR spectroscopy. At the end of the reaction 
the solution was evaporated under vacuum (77 mbar, 40 °C) in inert atmosphere: the obtained acyl 
chloride was employed without further purification for the subsequent reaction.  
All synthesized compounds were analyzed by FT-IR, 
1
H-NMR, 
13
C-NMR, UV and mass spectrometry. The 
instrumental results interpretation for all compounds is reported below; as an example, spectra are 
reported only for lynolenoyl-β-sitosterol.  
 
anhydrous toluene 
3h 
HO
DMPA 
R1COCl 
RO
R1COCl 
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PALMITOYL β-SITOSTEROL 
 
 
 
 
 
 
 
 
                                                                          R= 
 
Reaction parameters: 
 
Molar ratio palmitoyl chloride:β-sitosterol  1:1 
 
β-sitosterol  1.21x10
-3 
mol, 0.50 g,  
Palmitoyl chloride 1.21x10
-3
 mol, 0.33 g, 0.36 ml 
DMPA 1.73x10
-3 
mol, 0.21 g, 
Reaction temperature Room temperature 
Reaction time 12 h  
Yield 70% 
 
C45H80O2    MW = 653.2 
 
TLC: Hexane/Ethyl acetate/Ethyl Ether 5/2/1and spot visualization with iodine vapor 
 
UV/Vis in MeOH   λ (nm) =261; 280 
 
1
H-NMR (CDCl3): δ = 5.38-5.36 (m, 1 H, H7); 4.69-4.55 (m, 1 H, H2); 2.35-2.22 (m, 4 H, H1, H30); 2.04-0.80 (m, 
74 H, CH2 and CH3).  
 
 
HO
H
2
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13
C-NMR (CDCl3): 173.245 CO; 140.012 C6; 122.623 C7; 73.897 C2, 57.022 C14; 56.989 C17; 50.274 C10; 46.040 
C21; 42.225 C13; 39.873 C12; 38.373 C1; 37.215 C4; 36.797 C5; 35.154 C18; 34.828 C19; 34.528 C30;; 32.089 C9; 
32.024 C42; 29.987 C32; 29.865 C35; 29.647 C39, C41; 29.520 C33, C34; 29.504 C36, C37; 29.433 C24; 29.440 C38, 
C40; 28.572 C16; 27.406 C3; 26.129 C8; 25.123 C31; 24.516 C20; 23.417 C22; 21.199 C11; 20.031 C25, C26; 19.602 
C23; 19.243 C29; 19.015 C27; 14.226 CH3; 12.125, 12.077 C28. 
 
FT-IR (KBr) 
1/λ (cm-1) Attribution 
 
2952.16, 2853.91 ν C sp
3 
- H 
1735.11 ν C=O 
1465.63 δ CH2 
1168.12, 1135.45 ν C-O 
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OLEOYL β-SITOSTEROL 
 
 
 
 
 
 
      R=
O
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Reaction parameters: 
 
Molar ratio oleic acid:β-sitosterol  1:1 
 
Oleic acid 1.21x10
-3 
mol, 0.34 g, 0.38 ml 
Oxalyl chloride 7.64x10
-3 
mol, 0.96 g, 0.64 ml 
Β-sitosterol 1.21x10
-3
 mol, 0.50 g 
DMPA 1.73x10
-3 
mol, 0.21 g 
Reaction temperature Room temperature 
Reaction time 12 h  
Purification Gravimetric column (Ethyl acetate/hexane 9.5/0.5)  
Yield  35% 
 
C47H81O2     MW = 678.21 
 
TLC: Hexane/Ethyl acetate/Ethyl Ether 5/2/1and spot visualization with iodine vapor 
 
UV/Vis in MeOH    λ (nm) = 234; 268 
 
1
H-NMR (CDCl3): δ = 5.37-5.31 (m, 3 H, H7, H37, H38); 4.63-4.59 (m, 1 H, H2); 2.33-2.23 (m, 4 H, H1, H30); 2.02-
0.80 (m, 73 H, CH2 and CH3). 
 
HO
H
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13
C-NMR (CDCl3): 173.375 CO; 139.876 C6; 130.264, 129.987 C37, C38, 122.870 C7; 74.011 C2, 56.927 C14; 
56.375 C17; 49.998 C10; 45.897 C21; 42.225 C13; 39.886 C12; 38.501 C1; 37.115 C4; 36.842 C5; 35.246 C18; 
34.767 C19; 34.205 C30; 32.107 C9; 31.989 C44; 29.964 C35; 29.880 C40; 29.780 C42; 29.579 C41;29.502 C24; 
29.436 C 43; 29.402 C32; 29.305 C33, C34; 28.614 C16; 27.541, 27.479C36, C39; 27.429 C3; 26.219 C8; 25.098 C31; 
23.987 C20; 23.275 C22;22.745 C45; 21.207 C11; 20.009 C25, C26; 19.372 C23; 19.125 C29; 18.872 C27; 14.377 CH3; 
12.132, 12.096 C28. 
 
FT-IR (NaCl)  
1/λ (cm-1) Attribution 
 
2928.21, 2854.15 ν C sp
3 
- H 
1736.71 ν C=O 
1464.76 δ CH2 
1173.20 ν C-O 
799.98 δ HC=CH  trans 
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LINOLENOYL β-SITOSTEROL 
 
 
 
 
 
 
                   R= 
O
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Reaction parameters: 
 
Molar ratio linolenic acid:β-sitosterol  1:1 
 
Linolenic acid 1.21x10
-3 
mol, 0.34 g, 0.37 ml 
Oxalyl chloride 7.64x10
-3 
mol, 0.96 g, 0.64 ml 
β-sitosterol 1.21x10
-3
 mol, 0.50 g 
DMPA 1.73x10
-3 
mol, 0.21 g 
Reaction temperature Room temperature 
Reaction time 12 h  
Purification Gravimetric column (Ethyl acetate/hexane 9.5/0.5)  
Yield  42% 
 
C47H77O2     MW = 674.21     
TLC: Hexane/Ethyl acetate/Ethyl Ether 5/2/1and spot visualization with iodine vapor 
UV/Vis in MeOH    λ (nm) = 234; 268 
HO
H
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1
H-NMR (500 MHz, CDCl3): δ = 5.43-5.27 (m, 7 H, H7, H37, H38, H40, H41, H43, H44); 4.63-4.57 (m, 1 H, H2,); 2.80 
(t, J=5.5, 4 H, H39, H42), 2.32-2.26 (m, 4 H, H1, H30); 2.10-0.83 (m, 61 H, CH2 and CH3). 
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37 
 
 
 
 
 
 
 
13
C-NMR (CDCl3): δ = 173.477 CO; 139.935 C6; 132.153-127.342 C37, C38, C40, C41, C43, C44; 122.796 C7; 73.910 
C2, 56.922 C14; 56.278 C17; 50.270 C10; 46.072 C21; 42.542 C13; 39.958 C12; 38.389; 37.230 C1; 36.821 C5; 
36.374 C18; 34.919 C19; 34.177 C30; 32.101 C9; 29.790-29.305 C32-C35; 29.403 C24; 28.464 C16; 28.039 C36; 
27.418 C3; 26.342 C8; 25.842 C39; 25.741 C42; 25.259 C31; 24.516 C20; 23.304 C22; 21.258 C11; 20.766 C45; 
20.031 C25, C26; 19.531 C23; 19.265 C29; 19.000 C27; 14.484 CH3; 12.204, 12.075 C28. 
 
ppm (f1)
050100150200
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FT-IR(NaCl) 
 
4000.0 3800 3600 3400 3200 3000 2800 2600 2400 2200 2000 1900 1800 1700 1600 1500 1400 1300 1200 1100 1000 900 800 700 600.0
0.00
5.0
10.0
15.0
20.0
25.0
30.0
35.0
40.0
45.0
50.0
55.0
60.0
65.0
70.0
75.0
80.0
85.0
90.0
95.0
100.00
cm-1
%T 
 
 
 
1/λ (cm-1) Attribution 
 
2932.11, 2854.15 ν C sp
3 
- H 
1734.41 ν C=O 
1464.01 δ CH2 
1175.57 ν C-O 
803.55 δ HC=CH  trans 
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4.1.2 - HPLC METHOD DEVELOPMENT 
First, the solubility of β-sitosterol, oleic and linolenic acids and their esters in methanol and in acetonitrile 
was assessed. β-sitosterol, as well as oleic and linolenic acids, are very soluble in both methanol and 
acetonitrile, whereas their esters dissolve less easily in both solvents, but sufficiently to be analyzed in 
reverse phase HPLC. Then, several trials were performed in order to select the best analysis conditions, 
changing different HPLC parameters: stationary phase, mobile phase, flow rate. The following trials were 
performed: 
 
Stationary phase Mobile phase Flow rate (ml/min) λ (nm) T °C 
ODS Hypersil 250x4.6mm MeOH/H2O 80:20 0.8 ml/min 210 Room temp. 
ODS Hypersil 250x4.6mm MeOH/H2O 75:25 0.8 ml/min 210 Room temp. 
Symmetry Shield 250x4.6mm MeOH/H2O 75:25 0.4 ml/min 210 Room temp. 
X Bridge 250x4.6 mm MeOH/H2O 75:25 0.4 ml/min 210 Room temp. 
Symmetry Shield 250x4.6mm ACN/H2O 80:20 0.4 ml/min 210 Room temp. 
Symmetry Shield 250x4.6mm ACN/H2O 80:20 0.8 ml/min 210 Room temp. 
Symmetry Shield 250x4.6mm ACN/H2O 90:10 0.8 ml/min 210 Room temp. 
Alltima C-8 250x4.4 mm ACN/H2O 90:10 0.8 ml/min 210 Room temp. 
Alltima C-8 250x4.4 mm ACN/H2O 95:5  0.8 ml/min 210 Room temp. 
Alltima C-8 250x4.4 mm ACN/ H2O 95:5 1 ml/min 210 Room temp. 
Alltima C-8 250x4.4 mm ACN 100% 0.8 ml/min 210 Room temp. 
Alltima C-8 250x4.4 mm ACN 100%  1 ml/min 210 Room temp. 
 
Table 4. Conditions used in method development. 
 
All the trials reported in Table 4 were performed injecting β-sitosterol, oleic acid, linolenic acid, and their 
esterification products, separately.  
Acetonitrile (100%) resulted the best solvent to be used as mobile phase for our analysis, since the trials 
performed using a mixture of methanol and water showed a low peak resolution. Long retention time of 
the analytes made us to select a flow rate of 1.0 ml/min and a C-8 column, which resulted also in a good 
peak separation. 
A wavelength of 210 nm was chosen in order to detect both β-sitosterol and fatty acids. 
The selected analysis condition are: 
• Mobile phase: Acetonitrile 100% 
• Stationary phase: Alltima C-8 
• Flow rate: 1 ml/min 
• λ: 210 nm  
• Room temperature 
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The chromatograms of β-sitosterol (Fig. 4), linolenic acid (Fig. 5), oleoyl β-sitosterol (Fig. 6) and linolenoyl β-
sitosterol (Fig. 7) are reported below. 
 
 
 
 
 
 
 
 
 
 
Figure 4. Chromatogram of β-sitosterol. 
 
 
 
 
 
 
 
 
 
 
 
Figure 5. Chromatogram of linolenic acid. 
 
14
.
27
5
15
.
58
7
AU
0.00
0.02
0.04
0.06
0.08
0.10
0.12
0.14
Minutes
0.00 5.00 10.00 15.00 20.00 25.00 30.00
3.
65
5
4.
60
3
AU
0.00
0.10
0.20
0.30
0.40
0.50
0.60
Minutes
2.00 4.00 6.00 8.00 10.00 12.00
41 
 
 
 
 
 
 
 
 
 
 
 
Figure 6. Chromatogram of oleoyl β-sitosterol. 
 
 
 
 
 
 
 
 
 
 
Figure 7. Chromatogram of linolenoyl β-sitosterol. 
 
As seen in Fig. 4, β-sitosterol displayed two peaks having a similar retention time (14.275 and 15.587), due 
to its purity grade: 60%, the remaining 40% were other sterols. In addition, the purity grades of oleic and 
linolenic acids (Fig. 5) were 90% and 70%, respectively: as a result, the esters obtained using β-sitosterol 
and fatty acids showed multiple peaks having similar retention times. 
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4.1.3 - BIOCATALYTIC SYNTHESIS OF β-SITOSTEROL FATTY ESTERS 
In the first phase of the study, different enzymes were screened in order to select the most suitable for the 
proposed aim, namely the esterification of β-sitosterol with oleic acid and linolenic acid. 
In this phase different trials were performed in screw-cap test tubes, with a high amount of enzyme (140 
U/mg), a low concentration of substrates (1 mg/ml), used with a 1:1 molar ratio, and using heptane as 
reaction solvent (2 ml), since the bio-catalysts used prefer hydrophobic solvents: such conditions were 
shown to be the best ones in order to promote the full development of the reaction. 
The enzymes used in this phase were: 
• Amano lipase 
• Lipase from Candida cylindracea 
• Lipase from Rhizopus oryzae 
• Lipase from Candida rugosa 
• Lipase from Aspergillum oryzae 
TLC analyses were performed at different times of the reactions, showing that lipase from Candida 
cylindracea promotes the reaction with oleic acid, whereas lipase from Candida rugosa promotes the 
esterification of β-sitosterol with both oleic and linolenic acids. 
 
The second phase of this study was the optimization of the reaction conditions. Different parameters were 
screened: solvent, reaction temperature, lipase units, reaction time. Several trials in 2 ml of solvent were 
performed, changing one parameter at a time, and keeping the other variables constant. TLC technique was 
used to assess the results of the trials. The following parameters were changed: 
• Solvent: heptane, toluene, acetone, acetonitrile, hexane, isopropyl ether 
• Reaction temperature: 25 °C, 30 °C, 40 °C 
• Enzyme units : 140 U/mg, 70 U/mg , 35 U/mg, 28 U/mg, 14 U/mg 
The conditions found in this phase of the study are shown in Tables 5, 6, 7. 
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Oleoyl β-sitosterol 
 
Lipase from Candida rugosa 35 U/mg 
β-sitosterol 1 mg/ml 
Oleic acid 0.68 mg/ml
 *
 
Reaction solvent Toluene 
Reaction temperature 40 °C 
 
Table 5.  
 
Lipase from Candida cylindracea 14 U/mg 
β-sitosterol 1 mg/ml 
Oleic acid 0.68 mg/ml
 *
 
Reaction solvent Heptane 
Reaction temperature 40 °C 
 
Table 6. 
 
Linolenoyl β-sitosterol 
 
Lipase from Candida rugosa 35 U/mg 
β-sitosterol 1 mg/ml 
Linolenic acid 0.67 mg/ml
*
 
Reaction solvent Toluene 
Reaction temperature 40 °C 
 
Table 7. 
 
* = Fatty acid (oleic or linolenic) and β-sitosterol were used with a molar ratio of 1:1. 
 
Using the conditions found in the previous phase of the study, reactions on a semi-preparative scale (25 ml) 
were performed in order to evaluate the reaction’s kinetics and time. Samples (0.5 ml) were taken at fixed 
times (4 h, 24 h, 42 h, 48 h, 52 h, 72 h), centrifuged to eliminate the enzyme, dried under N2 flow, dissolved 
in the mobile phase and subsequently analyzed by HPLC using the conditions previously reported.  
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4.2 - RESVERATROL 
 
4.2.1 - CHEMICAL SYNTHESIS OF RESVERATROL FATTY ESTERS 
Resveratrol esters were obtained both with saturated (palmitic and stearic acid) and unsaturated (oleic, 
linoleic, and linolenic acid) fatty acids. 
 
 
 
R= R1CO- 
Scheme 3. 
Under nitrogen flow, resveratrol was dissolved in 20 ml anhydrous toluene and the solution was stirred at 
room temperature. Then TEA was added and, using an ice bath, the temperature was decreased until 0°C;  
afterwards the chloride was added dropwise. The reaction mixture thus obtained was carried to room 
temperature and magnetically stirred, repairing from daylight. 
The mixture was washed with saturated NaHCO3 water solution and then with water (3 x 20 ml). The 
organic layer was dried over anhydrous Na2SO4 and evaporate under vacuum (77 mbar, 40 °C). 
When the acyl chloride was not commercially available, it was prepared as follows: 
 
R1COOH     +   (COCl)2 
Scheme 4. 
The unsaturated fatty acid was dissolved in 20 ml anhydrous toluene and the solution was stirred at room 
temperature under anhydrous conditions. Then, using an ice bath, the temperature was decreased to 0 °C 
and oxalyl chloride was added dropwise. The reaction mixture was carried to room temperature and 
magnetically stirred for 3 h. The reaction was monitored by IR. At the end of the reaction the solution was 
evaporated under vacuum (77 mbar, 40 °C) in inert atmosphere: the obtained acyl chloride was employed 
without further purification the for subsequent reaction.  
All synthesized compounds were analyzed by FT-IR, 
1
H-NMR, 
13
C-NMR, UV and mass spectrometry. The 
instrumental results interpretation for all compounds is reported below; as example, 3,5,4’-tri-oleoyl 
resveratrol spectra are reported. 
3h 
anhydrous toluene 
R1COCl 
HO
HO
OH TEA 
RCOCl 
RO
RO
OR
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3,5,4’-TRIPALMITOYL RESVERATROL 
 
 
 
 
 
Reaction parameters: 
 
Molar ratio palmitoyl chloride:resveratrol  1:3 
Resveratrol 2.2x10
-3 
mol, 0.50 g 
Palmitoyl chloride 6.6x10
-3
 mol, 1.81 g, 2 ml 
TEA 6.6x10
-3 
mol, 0.67 g, 0.92 ml 
Reaction temperature Room temperature 
Reaction time 3 h  
Yield 70% 
 
C62H96O6     MW = 943.65 
 
TLC: Hexane/Acetone 1/1 
 
m/z: 965 [M+H]
+ 
 
UV/Vis in MeOH    λ (nm) = 232; 291 
 
1
H-NMR (, CDCl3): δ = 7.48 (d, J2’-3’ = 8.8, 2 H, H2’, H6’); 7.02-7.12 (m, 5 H, H2,H6, H3’, H5’, Hα); 7.01 (d, Jβ,α = 
15.8, 1 H, Hβ’); 6.80 (t, J4-6 = 1.8, 1 H, H4); 2.55 (t, J = 7.3, 6 H, H7); 1.79-1.68 (m, 6 H, H8); 1.35-1.26 (m, 72 H, 
H9-H20,); 0.91 (t, J=5.9, 9 H, CH3,). 
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13
C-NMR (CDCl3): δ =172.242 CO(C4’); 171.902 CO(C3), CO(C5); 151.724 C4’; 150.853 C3, C5; 139.707 C1; 
134.631 C1’, 129.865 Cα; 127.774 C2’, C6’; 127.516 Cβ; 122.053 C3’, C5’, 116.946 C2, C6; 114.560 C4; 34.624 C7; 
32.108 C19; 29.865 C12; 29.835 C17; 29.797 C9; 29.638 C16, C18; 29.524 C13, C14; 29.441 C17; 29.320 C10,C11; 
25.153 C8* 25.100 C8*; 22.849 C20; 14.227 CH3. 
*= the two chains give two different signals since they are not equivalent 
 
FT-IR (KBr) 
1/λ (cm-1) Attribution 
 
3064.65 ν C sp
2 
- H 
2954.16 ,2919.52, 2850.56 ν C sp
3 
- H 
1753.12 ν C=O 
1612.42, 1599.20, 1581.78 ν C=C  
1467.90 δ CH2 
1198.66, 1139.73 ν C-O 
971.67 δ HC=CH  trans 
720.95 δ HC= aromatic  
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3,5,4’-TRISTEAROYL RESVERATROL 
 
 
 
 
 
 
Reaction parameters: 
 
Molar ratio stearoyl chloride:resveratrol  1:3 
Stearoyl chloride 6.6x10
-3 
mol, 1.81 g, 2 ml 
Resveratrol 2.2x10
-3 
mol, 0.50 g 
TEA 6.6x10
-3 
mol, 0.67 g, 0.92 ml 
Reaction temperature Room temperature 
Reaction time 3 h  
Yield 63% 
 
C68H114O6     MW = 1026.52 
 
TLC: Hexane/Acetone 1/1 
 
m/z: 1049 [M+H]
+ 
 
UV/Vis in MeOH    λ (nm) = 228; 300; 310 
 
1
H-NMR (CDCl3): δ = 7.48 (d, J2’-3’ = 8.8, 2 H, H2’, H6’);7.02-7.12 (m, 5 H, H2,H6, H3’, H5’, Hα); 7.01 (d, Jα-β= 15.8, 
1 H, Hβ); 6.79 (t, J4-6 = 2.2, 1 H, H4); 2.55 (t, J = 7.3, 6 H, H7); 1.79-1.68 (m, 6 H, H8); 1.33-1.26 (m, 84 H, H9-
H22); 0.91 (t, J=5.9, 9 H, CH3). 
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13
C-NMR (CDCl3): δ =172.242 CO(C4’); 171.894 CO(C3), CO(C5); 151.724 C4’; 150.845 C3, C5; 139.707 C1; 
134.631 C1’; 129.857 Cα; 127.766 C2’, C6’; 127.509 Cβ; 122.053 C3’, C5’; 116.946 C2, C6; 114.552 C4; 34.616 C7; 
32.101 C21; 29.873 C12, C13; 29.838 C17; 29.631 C19 C16; 29.524 C14 ,C13; 29.434 C18, C9, C20; 29.312 C10,C11; 
25.145 C8* 25.100 C8*; 22.842 C22; 14.219 CH3. 
*= the two chains give two different signals since they are not equivalent 
 
FT-IR (KBr) 
1/ λ (cm-1) Attribution 
 
3064.65 ν C sp
2 
- H 
2954.16 ;2918.28; 2850.06 ν C sp
3 
- H 
1759.80 ν C=O 
1612.40; 1600.05; 1587.78 ν C=C  
1467.86 δ CH2 
1198.68; 1140.27 ν C-O 
971.02 δ HC=CH  trans 
720.97 δ HC= aromatic 
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3,5,4’-TRIOLEOYL RESVERATROL 
 
 
 
 
 
    
Reaction parameters: 
Molar ratio oleic acid:resveratrol  1:3 
Oleic acid  6.6x10
-3 
mol, 1.85 g, 2.08 ml 
Oxalyl chloride 4.38x10
-2 
mol, 5.52 g, 3.51 ml 
Resveratrol 2.2x10
-3 
mol, 0.5 g 
TEA 6.6x10
-3 
mol, 0.67 g, 0.92 ml 
Reaction temperature Room temperature 
Reaction time 20 h  
Yield 69% 
 
C68H108O6     MW = 1021.58    
TLC: Hexane/Acetone 1/1  
m/z: 1022 [M+H]
+ 
UV/Vis in MeOH    λ (nm) = 228; 298; 310 
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1
H-NMR (500 MHz, CDCl3): δ = 7.48 (d, J2’-3’ = 8.4, 2 H, H2’, H6’);7.10-7.02 (m, 5 H, H2,H6, H3’, H5’, Hα); 7.00 (d, 
Jα-β= 15.8, 1 H, Hβ); 6.80 (t, J4-6 = 1.8, 1 H, H4); 5.35 (m, 6H, H14, H16); 2.55 (t, J = 7.3, 6 H, H7); 2.35-2.03 (m,  
12 H, H13, H16); 1.79-1.68 (m, 6 H, H8); 1.35-1.20  (m, 60 H, H9-H12 and H17-H22); 0.91 (t, J=5.9, 9 H, CH3). 
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ppm (f1)
50100150
 
 
 
 
13
C-NMR (MHz, CDCl3): δ =172.220 CO(C4’) ; 171.871 CO(C3), CO(C5); 151.717 C4’; 150.845 C3, C5; 139.707 
C1; 134.631 C1’; 130.251 C14; 129.903 C15, Cα; 127.781 C2’, C6’; 127.524 Cβ; 122.053 C3’, C5’; 116.946 C2, C6; 
114.552 C4; 34.906 C7; 32.085 C21; 29.964 C12, 29.880 C17; 29.669 C19; 29.509 C18 ; 29.479 C20; 29.335 C9; 
29.282 C10, C11; 27.441 C13-C16; 27.373 C16-C13 ; 25.137, 25.077 C8*; 22.840 C22; 14.277 CH3. 
*= the two chains give two different signals since they are not equivalent 
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FT-IR (NaCl) 
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100.00
cm-1
%T 
 
 
1/ λ (cm-1) Attribution 
 
3064.65 ν C sp
2 
- H 
3005.07; 2925.38; 2854.23 ν C sp
3 
- H 
1764.11 ν C=O 
1610.66; 1600.36; 1589.14 ν C=C  
1464.75 δ CH2 
1198.51; 1165.62; 1127.11 ν C-O 
961.91 δ HC=CH  trans 
724.19 δ HC= aromatic   
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3,5,4’-TRILINOLEOYL RESVERATROL 
 
 
 
O
7
8
9
10
11
12
13
14 15
16
17 18
19
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R =
 
 
Reaction parameters: 
 
Molar ratio linoleic acid:resveratrol  1:3 
Linoleic acid  6.6x10
-3 
mol, 1.84 g, 2.04 ml 
Oxalyl chloride 4.36x10
-2 
mol, 5.50 g, 3.45 ml 
Resveratrol 2.2x10
-3 
mol, 0.5 g 
TEA 6.6x10
-3 
mol, 0.67 g, 0.92 ml 
Reaction temperature Room temperature 
Reaction time 20 h  
Yield 58% 
 
C68H102O6     MW = 1015.43    
 
TLC: Hexane/Acetone 1/1 
 
m/z: 1016[M+H]
+ 
 
UV/Vis in MeOH    λ (nm) = 228; 298; 310 
 
1
H-NMR (CDCl3): δ = 7.48 (d, J2’-3’ = 8.8, 2 H, H2’, H6’);7.11-7.03 (m, 5 H, H2,H6, H3’, H5’, Hα); 6.95 (d, Jα-β= 16.0, 
1 H, Hβ); 6.80 (t, J4-6 = 2.2, 1 H, H4); 5.35 (m, 12H, H14, H16,H17, H18,); 2.78 (t, J=5.5, 6 H, H16,); 2.55 (t, J = 7.3,  
6 H, H7,); 2.35-2.03 (m, 12 H, H13, H19,); 1.79-1.66 (m, 6 H, H8,); 1.37-1.23 (m, 42 H, H9-H12 and H20-H22,); 0.89 
(t, J=6.9, 9 H, CH3,). 
RO
OR
OR
5'
4'
3'
2'
6'
1'
β
α
2
3
4
5
6
1
54 
 
13
C-NMR (CDCl3): δ =172.331 CO(C4’) ; 171.995 CO(C3), CO(C5); 151.671 C4’; 150.792 C3, C5; 139.707 C1; 
134.623 C1’; 130.441 C14; 130.221 C17; 129.850 Cα; 128.342 C18; 128.137 C15; 127.812 C2’, C6’; 127.478 Cβ; 
122.084 C3’, C5’; 116.984 C2, C6; 114.598 C4; 34.609 C7; 31.745 C21; 29.812 C12; 29.555 C19;  29.365 C9 C20; 
29.305 C10, C11; 27.418 C13; 25.872 C16 ; 25.137, 25.084 C8*; 22.773 C22; 14.250 CH3. 
*= the two chains give two different signals since they are not equivalent 
 
FT-IR (NaCl) 
1/ λ (cm-1) Attribution 
 
3064.65 ν C sp
2 
- H 
3008.07; 2927.64; 2855.64 ν C sp
3 
- H 
1764.11 ν C=O 
1611.15; 1600.59, 1588.92 ν C=C  
1464.72 δ CH2 
1198.85; 1165.83, 1127.41 ν C-O 
961.92 δ HC=CH  trans 
728.86 δ HC= aromatic   
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3,5,4’-TRILINOLENOYL RESVERATROL 
 
 
 
 
 
     
O
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9
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Reaction parameters: 
 
Molar ratio linolenic acid:resveratrol  1:3 
Linolenic acid  6.6x10
-3 
mol, 1.83 g, 2.00 ml 
Oxalyl chloride 4.00x10
-2 
mol, 5.00 g, 2.38 ml 
Resveratrol 2.2x10
-3 
mol, 0.5 g 
TEA 6.6x10
-3 
mol, 0.67 g, 0.92 ml 
Reaction temperature Room temperature 
Reaction time 20 h  
Yield 43% 
 
C68H96O6     MW = 1009.53  
 
TLC: Hexane/Acetone 1/1 
 
m/z: 1022 [M+H]
+ 
 
UV/Vis in MeOH    λ (nm) = 228; 294; 310 
 
1
H-NMR (CDCl3): δ = 7.48 (d, J2’-3’ = 8.8, 2 H, H2’, H6’);7.10-7.05 (m, 5 H, H2,H6, H3’, H5’, Hα); 7.01 (d, Jα-β= 15.8, 
1 H, Hβ); 6.80 (t, J4-6 = 2.1, 1 H, H4); 5.35 (m, 18 H, H14, H16,H17, H18, H20, H21); 2.81 (t, J=5.5, 12 H, H16, H19); 
2.55 (t, J = 7.3, 6 H, H7); 2.35-2.03 (m, 12 H, H13, H22); 1.79-1.71 (m, 6 H, H8); 1.35-1.25 (m, 24 H, H9-H12 H17); 
0.91 (t, J=5.9, 9 H, CH3). 
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13
C-NMR (MHz, CDCl3): δ =172.227 CO(C4’) ; 171.879 CO(C3), CO(C5); 151.717 C4’; 150.838 C3, C5; 139.715 
C1; 134.631 C1’; 132.161 C21; 130.426 C14; 129.873 Cα; 128.531 C17-C18;128.471 C17-C18; 128.031 C15; 127.789 
C2’, C6’; 127.516 Cβ; 127.365 C20; 122.061 C3’, C5’; 116.954 C2, C6; 114.552 C4; 34.601 C7; 29.775 C12; 29.335 
C9; 29.282 C10,C11; 27.411 C13; 25.835 C16; 25.759 C19; 25.130-25.069 C8*; 20.743 C22; 14.401 CH3. 
*= the two chains give two different signals since they are not equivalent 
 
FT-IR (NaCl) 
1/ λ (cm-1) Attribution 
 
3064.65 ν C sp
2 
- H 
3005.07; 2925.38; 2854.23 ν C sp
3 
- H 
1764.11 ν –C=O 
1610.66; 1600.36; 1589.14 ν –C=C aromatic 
1464.75 δ CH2 
1198.51; 1165.62; 1127.11 ν C-O 
961.91 δ HC=CH  trans 
724.19 δ HC= aromatic  
3064.65 ν C sp
2 
- H 
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4.2.2 - HPLC METHOD DEVELOPMENT 
The solubility of resveratrol and its esters was screened: resveratrol resulted very soluble in methanol, 
whereas its derivatives showed a lower solubility. Thanks to these solubility tests we also found out that 
the addition of a little amount of water leads to the re-precipitation of resveratrol esters: hence, 100% 
methanol was chosen as mobile phase.  
Two different stationary phases were screened: C-18 Puro-sphestar 250x4.6 mm and C-8 Alltima 250x4.6 
mm. C-8 Alltima was selected, because of the higher resolution achieved. 
Different flow rates were tested as well: a 0.8 ml/min flow resulted in a good peak resolution, so it was 
selected for the analysis. 
The final analysis conditions are:   
• Mobile phase: 100% methanol 
• Stationary phase: C-8 Alltima 250x4.6 mm 
• Flow rate: 0.8 ml/min 
• λ: 300 nm 
• Room temperature 
The chromatograms of resveratrol (Fig. 8), 3,5,4’-tripalmitoyl resveratrol (Fig. 9), 3,5,4’-trioleoyl resveratrol 
(Fig. 10), 3,5,4’-trilinolenoyl resveratrol (Fig. 11) are reported below. 
 
 
 
 
 
 
 
 
 
Figure 8. Chromatogram of resveratrol. 
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Figure 9. Chromatogram of 3,5,4’-tripalmitoyl resveratrol. 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 10. Chromatogram of 3,5,4’-trioleoyl resveratrol. 
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Figure 11. Chromatogram of 3,5,4’-trilinolenoyl resveratrol. 
 
As seen in Figures 10 and 11, the triesters obtained from oleic and linolenic acids showed multiple peaks 
having similar retention times, due to the purity grade of the starting fatty acids, which was 90% for oleic 
acid and 70% for linolenic acid. The tri-esters obtained starting from palmitoyl chloride (Fig. 9), stearoyl 
chloride and linoleic acid had a higher purity, hence their chromatograms showed a main peak. 
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4.2.3 - BIOCATALYTIC SYNTHESIS OF RESVERATROL FATTY ESTERS 
Since chemical synthesis of resveratrol mono and diesters is not possible and given the presence in 
literature [154] of synthesis of these compounds by biocatalytic hydrolysis of triester, in the first phase of 
the study a screening on enzymes and reaction conditions was performed. The aim of this screening was to 
select the most suitable enzymes and reaction conditions for the synthesis of mono and diesters of 
resveratrol starting from triester.  
Different trials were performed in screw-cap test tubes, kept at 30 °C under magnetic stirring, using 2 ml of 
solvent, 2 mg/ml of substrate (trioleyol resveratrol) and 20 mg/ml of enzyme. These trials are reported in 
Table 8. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Table 8. 
 
All the trials listed in Table 8 were performed using trioleoyl resveratrol as substrate and analyzing the 
hydrolysis products by TLC (1/1 hexane/acetone). For each trial a blank reaction (set with only solvent and 
substrate) was carried out, in order to exclude any false result due to substrate degradation. TLC 
examination showed that only Acylase I from Aspergillus melleus and PPL in TRIS buffer / HCl solution 
(pH=8) were able to catalyze the hydrolysis of triester. 
Once the enzymes and the reaction medium have been selected, a new set of trials was prepared, 
increasing the substrate concentration (4 mg/ml): this increment resulted in a higher hydrolysis with both 
Solvent  Enzyme 
Toluene (95%) / Water (5%)  Protease 
Toluene (95%) / Water (5%) not immobilized CAL-B  
Toluene (95%) / Water (5%) PS-Amano lipase 
Toluene (95%) / Water (5%) Lipase G 
Acetate buffer pH=7 / Acetone (10%) Protease 
Acetate buffer pH=7 / Acetone (10%) not immobilized CAL-B 
Acetate buffer pH=7 / Acetone (10%) PS-Amano lipase 
Acetate buffer pH=7 / Acetone (10%) Lipase G 
Tris buffer / HCl pH=8 / DMSO (2%) Lipase from Candida rugosa 
Tris buffer / HCl pH=8 / DMSO (2%) Lipase from Rhizopus arrhizus 
Tris buffer / HCl pH=8 / DMSO (2%) PS-Amano lipase 
Tris buffer / HCl pH=8 / DMSO (2%) Acylase from Aspergillus melleus 
Tris buffer / HCl pH=8 / DMSO (2%) PPL (lipase from hog pancreas) 
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enzymes. The subsequent step was to perform tests on a larger scale (25 ml), in order to assess the time 
course of the reaction. At fixed times (4 h, 24 h, 48 h, 72 h, 96 h, 120 h), samples (0.5 ml) were taken, 
extracted with chloroform and then with ethyl acetate, treated with anhydrous Na2SO4, dried under N2 
flow, dissolved in the mobile phase and subsequently analyzed by HPLC using the conditions previously 
reported. These analyses showed that both enzymes promote the maximum production of mono and 
diesters at 96 h. A further increase of reaction time resulted in the formation of resveratrol, and thus in the 
complete hydrolysis of triester.    
In the case of biotransformation with Acylase I from Aspergillus melleus the reaction was set up on a semi-
preparative scale (100 ml) in order to isolate the final products in a sufficient amount for the structural 
characterization. To 400 mg of trioleoyl resveratrol dispersed in 4 ml of DMSO, 2 g of Acylase I from 
Aspergillus melleus and 100 ml of TRIS buffer/HCl pH=8 (prepared dissolving 1.2114 g of TRIS in 100 ml 
deionized water and adding HCl dropwise until pH 8 is reached) were added. 
After 96 hours the reaction mix was extracted with chloroform (2 x 40ml) and with ethyl acetate (1 x 40 ml). 
The organic layers were pooled and washed with saturated NaHCO3 water solution and then with water (3 x 
20 ml). The new organic layer was dried over anhydrous Na2SO4 and evaporated under vacuum; then, the 
evaporation residue was analyzed by HPLC. 
In order to characterize each analyte, the evaporation residue was separated using a chromatographic 
column with 7/3 hexane/acetone as mobile phase and a 1/60 product/silica ratio. Four different fractions 
were obtained in this separation, and subsequently analyzed. 
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4.2.4 - ORAL BIOAVALABILITY STUDIES OF RESVERATROL AND 3,5,4’-TRIOLEOYL RESVARATROL 
 IN THE RAT 
4.2.4.1 - STUDY PROTOCOL 
In order to check the oral bioavailability of 3,5,4’-trioleoyl resveratrol, preliminary tests were performed 
on rats, in collaboration with Dr. Giuseppe Rossoni from Dept. of Pharmacology, Chemotherapy and 
Medical Toxicology, Università degli Studi, Milan. 
For these studies 32 male Wistar rats were purchased from Charles River Italy (Calco, LC, Italy). Their initial 
weight was 250 ± 10 g and they were kept under automatically controlled conditions of temperature (21 ± 
1 °C), humidity (55 ± 5%) and light (12 h light + 12 h dark). Both water (Milan water supply network) and 
food (Mucedola Srl, Settimo Milanese, MI, Italia) were freely accessible to animals. 
All of the tests were performed in accordance with the Italian Government guidelines for laboratory 
animals and conformed with European Community Directives drawn up in November 1986 (86/609/EEC). 
Seven days after their arrival, the rats were randomly divided in two different experimental groups of 16 
animals (2 control rats + 14 treated rats), then starved for 24 hours before each treatment. Resveratrol 
was administered to the first group (20 mg/ml), whereas 3,5,4’-trioleoyl resveratrol was administered to 
the second group (90 mg/ml, corresponding to 20 mg/ml of resveratrol). Both resveratrol and 3,5,4’-
trioleoyl resveratrol were suspended in carboxymethyl cellulose (0.5 w/v) and administered to the animals 
orally, by using a gastric probe. The rats were anesthetized (sodium thiopental, 50 mg/kg i.p.) at fixed 
times (0.5, 1, 2, 3, 4, 6, 24 hours) in order to take blood samples, that were subsequently used to assess 
the bioavailability of resveratrol and its ester. Blood was collected from vena cava by using heparinized 
syringes, then placed in plastic tubes and centrifuged at 2000 x g for 15 minutes at 4 °C, in order to allow 
the separation of plasma. The plasma thus obtained was stored at -80 °C until it was analyzed (less than 
one week). Subsequently, plasma was extracted by using a suitable solvent and analyzed by HPLC/DAD.  
 
4.4.2.2- EXTRACTION METHOD DEVELOPMENT 
Before analyzing plasma samples by HPLC, the extraction method was developed.  
Two samples of plasma from control rats were added with solutions of resveratrol and 3,5,4’-trioleoyl 
resveratrol (at the same concentration), respectively. These samples were extracted using different 
procedures: 
Method 1: 70 µl of each sample were added with 10 µl of caffeine solution in methanol, then the resulting 
solutions were stirred for 30 seconds. Subsequently, the samples were added with 100 µl of acetonitrile, 
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stirred for 1 minute, centrifuged for 10 minutes at 800 rpm and the supernatant dried under N2; then the 
residues were re-dissolved in 50 µl of HPLC mobile phase (100% methanol). 
Method 2: 70 µl of each sample were added with 1 ml of acetone, stirred for 30 seconds, centrifuged for 1 
minute at 14000 rpm and the supernatant dried under N2; then the residues were re-dissolved in 50 µl of 
HPLC mobile phase (100% methanol). 
Method 3: 70 µl of each sample were added with 10 µl of caffeine solution in methanol, then the resulting 
solutions were stirred for 30 seconds. After, the samples were added with 100 µl of acetone, stirred for 1 
minute, centrifuged for 10 minutes at 800 rpm and the supernatant dried under N2; then the residues were 
re-dissolved in 50 µl of HPLC mobile phase (100% methanol). 
The extracts obtained using each method were analyzed by HPLC (analysis condition previously described) 
and % recovery was calculated (sample area/standard area) in order to select the best extraction 
procedure. Resveratrol and 3,5,4’-trioleoyl resveratrol standard solutions were prepared at the same 
concentration of the solutions added in the samples. 
Standard areas and sample areas along with their respective % recovery values are reported in Table 9. 
 
 
Reveratrol area 
Trioleoyl 
resveratrol area 
Resveratrol 
recovery (%) 
Trioleoyl 
resveratrol 
recovery (%) 
Standard 3230428 5102418 - - 
Method 1 194453 11832 6.02 0.23 
Method 2 1545366 2910922 47.83 57.04 
Method 3 1080340 2530835 33.44 30.16 
 
Table 9. 
Method 2 resulted the most efficient. Hence, the rat plasma samples were extracted using this method and 
subsequently analyzed by HPLC in triplicate. 
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4.3 – QUERCETIN 
 
4.3.1 - CHEMICAL SYNTHESIS OF QUERCETIN FATTY ESTERS 
Quercetin esters were obtained both with saturated (palmitic and stearic acid) and unsaturated (oleic, 
linoleic, and linolenic acid) fatty acids. 
 
 
      
 
 
                                                                                                        R= H or R1CO- 
Scheme 5. 
Under nitrogen flow, quercetin was dissolved in 10 ml of anhydrous dioxane and the solution was stirred at 
room temperature. Then TEA was added and, using an ice bath, the temperature was decreased until 0°C;  
afterwards the chloride was added dropwise. The reaction mixture thus obtained was stirred, repairing 
from daylight. 
The mixture was evaporated under vacuum (107mbar, 40°C); the residue was dissolved in 20 ml of 
chloroform and washed with saturated NaHCO3 water solution and then with water (3 x 20 ml). The organic 
layer was dried over anhydrous Na2SO4 and evaporate under vacuum. 
When the acyl chloride was not commercially available, it was prepared following the procedure previously 
described at page 44. 
All synthesized compounds were analyzed by FT-IR, 
1
H-NMR, 
13
C-NMR, UV and mass spectrometry. The 
instrumental results interpretation for all compounds is reported below; as an example, 3,5,7,3’,4’-
pentaoleoyl quercetin, 3,7,3’,4’-tetraoleoyl quercetin and 3,7,(3’/4’)-tri-oleoyl quercetin spectra are 
reported.  
 
HO
OH
O
O
OH
OH
OH
TEA RO
OR
O
O
OR
OR
OR
RCOCl 
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3,5,7,3’,4’-PENTAPALMYTOIL QUERCETIN 
 
 
 
 
 
Reaction parameters: 
 
Molar ratio palmytoil chloride:quercetin  1:7.5 
Quercetin 3.3x10
-4 
mol, 0.10 g,  
Palmytoil chloride 2.47x10
-3 
mol, 0.68 g, 0.75 ml 
TEA 2.47x10
-3 
mol, 0.25 g, 0.35 ml 
Reaction temperature Room temperature 
Reaction time 3 h  
Purification Crystallization with ethanol 
Yield 40% 
               
C95H160O12     MW = 1495,18     
 
TLC: Hexane/Acetone 9/1. In order to evidence the presence of residual quercetin, ethyl acetate 100% was 
used. 
 
m/z: 1496 [M+H]
+ 
 
UV/Vis in CHCl3     λ (nm) = 256; 300 
 
1
H-NMR (CDCl3): δ = 7.70 (dd, J6’-5’ = 8.1, J6’-2’ = 2.0, 1 H, H6’); 7.65 (d, J2’-6’ = 2.0, 1 H, H2’); 7.32 (d, J5’-6’ = 8.1,   
1 H, H5’); 7.30 (d, J6-8 = 2.5, 1 H, H8); 6.84 (d, J8-6 = 2.5, 1 H, H6); 2.72 (t, J = 7.6, 2 H, H12 in C5); 2.63-2.52 (m,   
8 H, H12); 1.78-1.67 (m, 10 H, H13), 1.52-1.26 (m, 120 H, H14-H25); 0.87 (t, J = 5.9, 15 H, CH3). 
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13
C-NMR (CDCl3): δ = 172.09 CO(C5) ; 170.92, 170.76, 170.73, 170.66 CO; 170.11 C4; 157.11 C9; 154.56 C7; 
153,79 C2; 150.88 C5, 144.74 C4’; 142.56 C3’; 134.39 C3; 128.02 C1’; 126.49 C6’; 123.99 C5’, C2’; 115.08 C10; 
114,04 C6, 108.95 C8, 34.62, 34.33, 34.27, 34.01 C12; 31.12 C24; 29.88 -29.26 C14-C23, 25.12, 24.95, 24.87, 
24.67 C13; 22.86 C25; 13.23 CH3. 
 
FT-IR (KBr) 
 1/λ (cm-1) Attribution 
 
2956.78; 2917.82; 2850.03 ν C sp
3
- H 
1769.36 ν C=O 
1641.86 ν C=O α,β unsaturated 
1468.42; 1439.79 δ C=C 
1268.31; 1242.04; 1208.39; 1189.18; 1114.42 ν C-O 
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3,5,7,3’,4’-PENTASTEAROYL QUERCETIN 
 
 
 
 
 
 
Reaction parameters: 
 
Molar ratio stearoyl chloride:quercetin  1:7.5 
Quercetin 3.3x10
-4
 mol, 0.10 g 
Stearoyl chloride 2.47x10
-3 
mol, 0.75 g, 0.84 ml 
TEA 2.47x10
-3 
mol, 0.25 g, 0.35 ml 
Reaction temperature Room temperature 
Reaction time 3 h  
Purification Crystallization with ethanol 
Yield 57% 
               
C105H180O12     MW = 1635,7     
 
TLC: Hexane/Acetone 9/1. In order to evidence the presence of residual quercetin, ethyl acetate 100% was 
used.  
 
m/z: 1636 [M+H]
+ 
 
UV/Vis in CHCl3     λ (nm) = 257; 298 
 
1
H-NMR (CDCl3): δ = 7.70 (dd, J6’-5’ = 8.3, J6’-2’ = 1.8, 1 H, H6’); 7.66 (d, J2’-6’ = 1.8, 1 H, H2’); 7.32 (d, J5’-6’ = 8.3,   
1 H, H5’); 7.31 (d, J6-8 = 2.2, 1 H, H8); 6.83 (d, J8-6 = 2.2, 1 H, H6); 2.73 (t, J = 7.6, 2 H, H12(C5)); 2.62-2.52 (m, 8 
H, H12); 1.78-1.71 (m, 10 H, H13), 1.55-1.26 (m, 100 H, H14-H27); 0.88 (t, J = 5.6, 15 H, CH3). 
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13
C-NMR (CDCl3): δ = : 172.25 (CO)C5 ; 171.04, 170.87 , 170.79 CO; 170.17 C4; 157.09 C9; 154.53 C7; 153,80 
C2; 150.81 C5, 144.71 C4’; 142.52 C3’; 134.43 C3; 128.00 C1’; 126.57 C6’; 124.05 C5’, C2’; 115.04 C10; 114,10 C6, 
109.07 C8, 34.63, 34.35, 33.40, 34.27, 34.02 C12; 32.16 C26; 29.95-29.28 C14- C25; 25.13, 24.97, 24.88, 24.69 
C13; 22.91 C27; 13.34 CH3. 
 
FT-IR (KBr) 
1/λ (cm-1) Attribution 
 
2956.62; 2918.33; 2850.34 ν C sp
3
- H 
1764.58 ν C=O 
1654.61 ν C=O α,β unsaturated 
1468.24; 1437.97 δ C=C 
1266.03; 1233.10; 1208.25; 1178.50; 1112.17 ν C-O 
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3,7,3’,4’-TETRASTEAROYL QUERCETIN 
 
 
 
 
 
 
 
Reaction parameters: 
 
Molar ratio stearoyl chloride:quercetin  1:4 
Quercetin 3.3x10
-4
 mol, 0.10 g 
Stearoyl chloride 1.32x10
-3 
mol, 0.40 g, 0.45 ml 
TEA 2.47x10
-3 
mol, 0.13 g, 0.18 ml 
Reaction temperature 10 °C 
Reaction time 3 h  
Yield 53% 
               
C87H146O10     MW = 1369,18     
 
TLC: Hexane/Acetone 9/1. In order to evidence the presence of residual quercetin, ethyl acetate 100% was 
used. 
 
m/z: 1370 [M+H]
+ 
 
UV/Vis in CHCl3     λ (nm) = 260; 300 
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1
H-NMR (CDCl3): δ =12.12 (s, 1 H, OH exch. D2O), 7.72 (dd, J2’-5’ =2.1, J6’-5’ =8.4, 2 H, H2’, H6’), 7.35 (d, J5’-6’=8.4, 
1 H, H5’), 6.84 (d, J8-6 = 2.1, 1 H, H8), 6.58 (d, J6-8 = 2.1, 1 H, H6), 2.67-2.52 (m, 8 H, H12); 1.75-1.71 (m, 8 H, 
H13); 1.26-1.05 (m, 112 H, H14-H27); 0.88 (t, J=6.1, 12 H, CH3) 
 
13
C-NMR (CDCl3): δ = 176.52 C4; 171.30, 170.86 , 170.76, 170.17 CO ; 161.96 C5; 156.71 C7; 156.18 C9; 
155.75 C2; 145.02 C4’;  142.60 C3’; 132.48 C3; 127.72 C1’; 126.64 C6’; 124.22 C2’, C5; 108.98 C10; 105.69 C6, 
101.34 C8; 34.63, 34.33, 34.27, 33.97 C12; 32.14 C26; 29.93-29.27 C14-C25; 26.54, 25.12, 24.89, 24.68 C13; 
22.90 C27; 13.31 CH3 
 
FT-IR (NaCl) 
1/λ (cm-1) Attribution 
 
3436.32 ν OH 
2956.72; 2918.51; 2850.40 ν C sp
3
- H 
1766.06 ν C=O 
1654.93 ν C=O α,β unsaturated 
1468.28; 1437.94 δ C=C 
1266.39; 1233.69; 1195.61; 1178.02; 1144.98 ν C-O 
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3,5,7,3’,4’-PENTAOLEOYL QUERCETIN 
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Reaction parameters: 
Molar ratio oleic acid:quercetin  1:7.5 
Oleic acid 2.47x10
-3 
mol, 0.70 g, 0.77 ml 
Oxalyl chloride 0.016 mol, 2.07 g, 1.31 ml 
Quercetin 3.3x10
-4
 mol, 0.10 g 
TEA 2.47x10
-3 
mol, 0.25 g, 0.35 ml 
Reaction temperature Room temperature 
Reaction time 20 h  
Yield  60% 
    
C105H170O12     MW = 1624,47     
TLC: Hexane/Acetone 9/1. In order to evidence the presence of residual quercetin, ethyl acetate 100% was 
used. 
m/z: 1625 [M+H]
+ 
UV/Vis in CHCl3     λ (nm) = 250; 296 
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7
.31
10
.00
170
.20
 
 
 
 
1
H-NMR (500 MHz, CDCl3): δ = 7.73 (dd, J6’-5’ = 8.0, J6’-2’ = 2.0, 1 H, H6’); 7.69 (d, J2’-6’ = 2.0, 1 H, H2’); 7.32 (d, 
J5’-6’ = 8.0, 1 H, H5’); 7.31 (d, J6-8 = 2.2, 1 H, H8); 6.86 (d, J8-6 = 2.2, 1 H, H6); 5.6-5.3 (m, 10 H, H19-H20); 2.75 (t, J 
= 7.6, 2 H, H12(C5)); 2.65-2.55 (m, 8 H, H12); 2.05 (m, 20 H, H18, H21); 1.82-1.70 (m, 10 H, H13), 1.48-1.20 (m, 
100 H, H14-H17 and H22-H27); 0.90 (t, J = 6.6, 15 H, CH3). 
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13
C-NMR (CDCl3): δ = 171.27 CO(C5); 170.07, 169.91, 169.87, 169.83 CO; 169.25 C4; 156.17 C9; 153.61 C7;  
152,9 C2; 149.9 C5, 143.79 C4’;  141.61 C3’; 133.42 C3; 129.38-128.92 C19, C20; 127.09 C1’; 125.65 C6’; 123.13 
C5’; 123.09 C2’;  114.13 C10; 113,17 C6, 108.13 C8, 33.69, 33.43, 33.40, 33.34, 33.07 C12; 31.26 C26; 29.08-
28.32 C14-C17 and C22-C25; 26.54, 26.52, 26.48, 26.47 C18, C21; 24.20, 24.17, 24.01, 23.92, 23.37 C13; 22.00, 
21.98, 21.96 C27; 13.40 CH3. 
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FT-IR (NaCl) 
 
4000.0 3800 3600 3400 3200 3000 2800 2600 2400 2200 2000 1900 1800 1700 1600 1500 1400 1300 1200 1100 1000 900 800 700 600.0
0.00
5.0
10.0
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95.0
100.00
cm-1
%T 
 
 
1/λ (cm-1) Attribution 
 
3005.42; 2924.95; 2854.29 ν C sp
3 
- H 
1770.90 ν C=O 
1652.88 ν C=O α,β unsaturated 
1465.64; 1434.78 δ C=C 
1266.04; 1234.19; 1205.04; 1178.27; 1114.74 ν C-O 
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3,7,3’,4’-TETRAOLEOYL QUERCETIN 
ORO
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Reaction parameters: 
Molar ratio oleic acid:quercetin 1:5 
Oleic acid 1.65x10
-3 
mol, 0.47 g, 0.52 ml 
Oxalyl chloride 0.011 mol, 1.38 g, 0.88 ml 
Quercetin 3.3x10
-4
 mol, 0.10 g 
TEA 1.65x10
-3 
mol, 0.17 g, 0.23 ml 
Reaction temperature Room temperature 
Reaction time 20 h  
Yield 65% 
 
C87H138O11     MW = 1359,47     
TLC: Hexane/Acetone 9/1. In order to evidence the presence of residual quercetin, ethyl acetate 100% was 
used. 
m/z: 1360 [M+H]
+ 
UV/Vis in CHCl3     λ (nm) = 269; 337 
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ppm (f1)
0.05.010.0
0
.95
5
.83
8
.00
136
.07
 
 
 
 
1
H-NMR (500 MHz, CDCl3): δ =12.14 (s, 1 H, OH exch. D2O), 7.75 (dd, J2’-5’ =2.0, J6’-5’ =8.5, 1 H, H6’),7.73 (d, J= 
2.0, 1 H, H2’),7.37 (d, J5’-6’=8.5, 1 H, H5’), 6.87 (d, J8-6 = 2.0, 1 H, H8), 6.61 (d, J6-8 = 2.0, 1 H, H6), 5.41-5.35 (m, 8 
H, H19-H20); 2.67-2.57 (m, 8 H, H12); 2.05 (m, 16 H, H18, H21); 1.81-1.74 (m, 8 H, H13); 1.44-1.29 (m, 80H, H14-
H17 and H22-H27); 0.90 (t, J=6.6, 12 H, CH3). 
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13
C-NMR (CDCl3): δ =174.60 C4; 170.34, 169.93, 169.89, 169,81 CO; 161.04 C5; 155.78 C7; 155.26 C9; 154.83 
C2; 144.08 C4’;  141.67 C3’; 131.57 C3; 129.40-128.90 C19, C20; 126.78 C1’; 125.76 C6’; 123.24 C2’, C5; 108.06 C10; 
104.77 C6, 100.57 C8; 33.71, 33.39, 33.34, 33.04 C12; 31.26 C26; 29.07-28.31 C14-C17 and C22-C25; 26.54, 26.52, 
26.47 C18, C21; 24.19, 24.17, 24.07, 23.92, C13; 21.98 C27; 13.40 CH3. 
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FT-IR (NaCl) 
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1/λ (cm-1) Attribution 
 
3517.78 ν OH 
3135.90; 3070.52; 3008.25 ν C sp
2 
- H 
2922.13; 2853.12 ν C sp
3 
- H 
1767.38 ν C=O 
1650.65 ν C=O α,β unsaturated 
1605.48; 1488.18; 1467.84 δ C=C 
1296.70; 1223.94; 1202.91; 1186.96; 1113.52 ν C-O 
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3,7,(3’/4’)-TRIOLEOYL QUERCETIN 
 
 
 
 
 
Reaction parameters: 
Molar ratio oleic acid:quercetin 1:4 
Oleic acid 1.32x10
-3 
mol, 0.37 g, 0.41 ml 
Oxalyl chloride 8.87x10
-
3 mol, 1.12 g, 0.7 ml 
Quercetin 3.3x10
-4
 mol, 0.10 g 
TEA 1,32x10
-3 
mol, 0.13 g, 0.18 ml 
Reaction temperature Room temperature 
Reaction time 20 h  
Yield 14% 
 
Using this molar ratio (1:4) both tri and tetraesters of quercetin were obtained. The two esters were then 
separated by chromatography, using a silica gel gravimetric columm (eluent hexane:acetone 9:1, ratio raw 
material/silica 1:60). 
C69H106O10     MW = 1095,47     
TLC: Hexane/Acetone 9/1. In order to evidence the presence of residual quercetin, ethyl acetate 100% was 
used. 
m/z: 1096  [M+H]
+ 
UV/Vis in CHCl3     λ (nm) = 250; 271; 316; 366 
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ppm (f1)
5.010.0
0
.89
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6
.00
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1
H-NMR (500 MHz, CDCl3): δ = 11.61 (s, 1 H, OH exch. D2O), 8.14 (dd, J6’-5’=8.5, J6’-2’ = 2.1, 1 H, H6’), 8.08 (d, 
J2’-6’ = 2.0, 1 H, H2’), 7.38 (d, J5’-6’ = 8.5, 1 H, H5’), 6.90 (d, J8-6 = 1.9, 1 H, H8), 6.8-6.7 (s, 1 H, OH exch. D2O), 
6.59 (d, J6-8 = 2.0, 1H, H6), 5.40-5.31 (m, 8 H, H19-H20); 2.06-2.57 (m, 6 H, H12); 2.06-2.02 (m, 12 H, H18, H21); 
1.82-1.78 (m, 6 H, H13), 1.48-1.28 (m; 60 H, H14-H17 and H22-H27), 0.92 (t, J=5.9, 9 H, CH3). 
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13
C-NMR (CDCl3): δ = 175.15 C4; 170.46, 170.22, 169.99 CO; 159.98 C5; 155.82 C7; 154.98 C9; 143.79 C2; 
143.22 C4’; 141.69 C3’; 136.39 C3;129.40-128.94 C19, C20; 128.09 C1’; 125.32 C6’; 123.11 C5’; 122.39 C2’; 106.27 
C10; 103.87 C6; 100.57 C8; 33.73, 33.43, 33.37 C12; 31.21 C26; 29.07-28.34  C14-C17 and C22-C25; 26.54, 26.48 
C18, C21; 24.20, 24.09 C13; 21.98 C27; 13.40 CH3. 
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FT-IR (NaCl) 
 
4000.0 3800 3600 3400 3200 3000 2800 2600 2400 2200 2000 1900 1800 1700 1600 1500 1400 1300 1200 1100 1000 900 800 700 600.0
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cm-1
%T 
 
 
1/λ (cm-1)  Attribution 
 
3321.56 ν OH 
3099.91; 3005.01 ν C sp
2 
- H 
2959.22; 2854.40 ν C sp
3 
- H 
1765.07 ν C=O 
1647.08 ν C=O α,β unsaturated  
1602.99; 1562.62; 1488.98; 1465.92 δ C=C 
1308.35; 1262.86; 1179.44; 1111.40 ν C-O 
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3,5,7,3’,4’-PENTALINOLEOYL QUERCETIN 
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Reaction parameters: 
 
Molar ratio linoleic acid:quercetin  1:7.5 
Linoleic acid 2.47x10
-3 
mol, 0.69 g, 0.76 ml 
Oxalyl chloride 0.016 mol, 2.07 g, 1.31 ml 
Quercetin 3.3x10
-4
 mol, 0.10 g 
TEA 2.47x10
-3 
mol, 0.25 g, 0.35 ml 
Reaction temperature Room temperature 
Reaction time 20 h  
Yield  85% 
    
C105H160O12     MW = 1613,47     
 
TLC: Hexane/Acetone 9/1. In order to evidence the presence of residual quercetin, ethyl acetate 100% was 
used. 
 
m/z: 1614 [M+H]
+ 
 
UV/Vis in CHCl3     λ (nm) = 281 
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1
H-NMR (CDCl3): δ = 7.70 (dd, J6’-5’ = 8.2, J6’-2’ = 1.8, 1 H, H6’); 7.66 (d, J2’-6’ = 1.8, 1 H, H2’); 7.33 (d, J5’-6’ = 8.2, 1 
H, H5’); 7.32 (d, J6-8 = 2.4, 1 H, H8); 6.84 (d, J8-6 = 2.1, 1 H, H6); 5.46-5.26 (m, 20 H, H19,H20,H22, H23); 2.77 (t, J = 
5.5, 10 H, H21 ); 2.69-2.41 (m, 10 H, H12); 2.10 (m, 20 H, H18, H24); 1.78-1.71 (m, 10 H, H13), 1.36-1.07 (m, 70 
H, H14-H17 and H25-H27); 0.89 (t, J = 6.1, 15 H, CH3). 
 
13
C-NMR (CDCl3): δ = 172.19 CO(C5); 170.98, 170.79, 170.74, 170.18 CO; 169.79 C4; 157.10 C9; 154.53 C7; 
153,84 C2; 150.81 C5, 144.71 C4’; 142.53 C3’; 134.33 C3; 130.47-128.08 C19, C20, C22, C23; 128.01 C1’; 126.58 C6’; 
124.05 C2’, C5’; 115.05 C10; 114.08 C6, 109.05 C8, 34.60, 34.31, 34.25, 34.08, 33.98 C12; 31.74 C26; 29.87-29.06 
C14-C17 and C25; 27.43 C18, C24; 25.87C21; 25.11, 24.93, 24.83; 24.67, 24.43C13; 22.80 C27; 13.29 CH3. 
 
FT-IR (NaCl) 
1/λ (cm-1) Attribution 
 
3009.81; 2926.55; 2855.30 ν C sp
3 
- H 
1771.48 ν C=O 
1653.51 ν C=O α,β unsaturated 
1464.98; 1433.96 δ C=C 
1265.09; 1233.19; 1203.86; 1177.03; 1115.73 ν C-O 
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3,7,3’,4’-TETRALINOLEOYL QUERCETIN 
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Reaction parameters: 
 
Molar ratio linoleil acid:quercetin  1:5 
Linoleic acid 1.65x10
-3
 mol, 0.46 g, 0.51 ml 
Oxalyl chloride 0.011 mol, 1.38 g, 0.88 ml 
Quercetin 3.3x10
-4 
mol, 0.10 g 
TEA 1.65x10
-3
 mol, 0.17 g, 0.23 ml 
Reaction temperature Room temperature 
Reaction time 20 h  
Yield  56% 
    
C87H140O11     MW = 1351,47     
 
TLC: Hexane/Acetone 9/1. In order to evidence the presence of residual quercetin, ethyl acetate 100% was 
used. 
 
m/z: 1352 [M+H]
+ 
 
UV/Vis in CHCl3     λ (nm) = 273; 339 
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1
H-NMR (CDCl3): δ = 12.12 (s, 1 H, OH exch. D2O), 7.72 (dd, J2’-5’ =2.1, J6’-5’ =8.2, 2 H, H2’ , H6’), 7.34 (d, J5’-
6’=8.2, 1 H, H5’), 6.84 (d, J8-6 = 1.8, 1 H, H8), 6.58 (d, J6-8 = 1.8, 1 H, H6), 5.45-5.29 (m, 16 H, H19-H20,H22-H23); 
2.77 (t, J=5.5, 8 H, H21,); 2.66-2.53 (m, 8 H, H12); 2.00 (m, 16 H, H18, H24); 1.75-1.56 (m, 8 H, H13); 1.29-1.25 
(m, 56H, H14-H17 and H25-H27); 0.88 (t, J=6.8, 12 H, CH3). 
 
13
C-NMR (CDCl3): δ = 176.52 C4; 171.29 ,170.85, 170.81, 170.74 CO; 161.96 C5; 156.70 C7; 156.19 C9; 155.74 
C2; 145.00 C4’; 142.60 C3’; 133.48 C3; 130.48-128.08 C19, C20, C22, C23; 127.74 C1’; 126.69 C6’; 124.21 C2’, C5; 
108.98 C10; 105.70 C6, 101.35 C8; 34.63, 34.31, 34.26, 33.96 C12; 31.75 C26; 29.85-29.25 C14-C17 and C25; 27.43 
C18, C24;25.87 C21; 25.11, 24.99, 24.89 C13; 22.80 C27; 14.30 CH3. 
 
FT-IR (NaCl) 
1/λ (cm-1) Attribution 
 
3009.59; 2927.35; 2855.56 ν C sp
3 
- H 
1772.46 ν C=O 
1654.85 ν C=O α,β unsaturated 
1465.42; 1433.99 δ C=C 
1266.25; 1235.50; 1196.53; 1179.28; 1127.48 ν C-O 
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3,7,(3’/4’)-TRILINOLEOYL QUERCETIN 
 
 
 
   
 
Reaction parameters: 
 
Molar ratio linoleic acid:quercetin 1:4 
Linoleic acid 1.32x10
-3 
mol, 0.37 g, 0.41 ml 
Oxalyl chloride 8.87x10
-3
 mol, 1.12 g, 0.7 ml 
Quercetin 3.3x10
-4
 mol, 0.10 g 
TEA 1,32x10
-3 
mol, 0.13 g, 0.18 ml 
Reaction temperature Room temperature 
Reaction time 20 h  
Yield 16% 
 
Using this molar ratio (1:4) both tri and tetraesters of quercetin were obtained. The two esters were then 
separated by chromatography, using a silica gel gravimetric columm (eluent hexane:acetone 9:1, ratio raw 
material/silica 1:60). 
C69H100O10     MW = 1089.32     
 
TLC: Hexane/Acetone 9/1. In order to evidence the presence of residual quercetin, ethyl acetate 100% was 
used. 
 
m/z: 1090 [M+H]
+ 
 
UV/Vis in CHCl3     λ (nm) = 269; 311; 359 
 
ORO
OH
OR
O(HoR)
O(HoR)
O
8
9
56
7
4
3
2
2'
3'
5'
4'
6'
1'
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88 
 
1
H-NMR (CDCl3): δ = 11.64 (s, 1 H, OH exch. D2O), 8.12 (dd, J6’-5’=8.5, J6’-2’ = 2.1, 1 H, H6’), 8.05 (d, J2’-6’ = 1.8, 1 
H, H2’), 7.36 (d, J5’-6’ = 8.5, 1 H, H5’), 6.88 (d, J8-6 = 2.1, 1 H, H8), 6.85-6.70 (s, 1 H, OH exch. D2O), 6.57 (d, J6-8 = 
2.1, 1H, H6), 5.45-5.26 (m, 12 H, H19-H20,H22-H23); 2.77 (t, J=5.5, 6 H, H21); 2.66-2.53 (m, 6 H, H12); 2.07-2.00 
(m, 12 H, H18, H24); 1.75-1.59 (m, 6 H, H13), 1.30-1.21 (m, 42H, H14-H17 and H25-H27), 0.88 (t, J=6.7, 9 H, CH3). 
 
13
C-NMR (CDCl3): δ = 176.52 C4; 171.39, 171.15, 170.91 CO; 160.90 C5; 156.71 C7; 155.88 C9; 144.71 C2; 
144.11 C4’; 142.59 C3’; 137.37 C3; 130.47-128.10 C19, C20, C22, C23; 129.03 C1’; 126.27 C6’; 124.02 C5; 123.29 
C2’; 107.20 C10; 104.78 C6, 101.47 C8; 34.64, 34.34, 34.28 C12; 31.75 C26; 29.85-29.26 C14-C17 and C25; 27.43 
C18,;25.87 C21, C24; 25.16, 25.00 C13; 22.80 C27; 14.30 CH3. 
 
FT-IR (NaCl) 
1/λ (cm-1)  Attribution 
 
3351.56 ν OH 
3009.50; 3005.01 ν C sp
2 
- H 
2927.46; 2855.61 ν C sp
3 
- H 
1771.37 ν C=O 
1651.79 ν C=O α,β unsaturated  
1605.85; 1562.62; 1492.00; 1465.84 δ C=C 
1307.00; 1268.23; 1194.05; 1133.49 ν C-O 
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3,5,7,3’,4’-PENTALINOLENOYL QUERCETIN 
ORO
OR
OR
OR
OR
O
8
9
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7
4
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2
2'
3'
5'
4'
6'
1'
10
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R =  
 
Reaction parameters: 
 
Molar ratio linolenil acid:quercetin  1:7.5 
Linolenil acid 2.47x10
-3 
mol, 0.69 g, 0.75 ml 
Oxalyl chloride 0.016 mol, 2.07 g, 1.31 ml 
Quercetin 3.3x10
-4
 mol, 0.10 g 
TEA 2.47x10
-3 
mol, 0.25 g, 0.35 ml 
Reaction temperature Room temperature 
Reaction time 20 h  
Yield  74% 
    
C105H150O12     MW = 1587.18     
 
TLC: Hexane/Acetone 9/1. In order to evidence the presence of residual quercetin, ethyl acetate 100% was 
used. 
 
m/z: 1588 [M+H]
+ 
 
UV/Vis in CHCl3     λ (nm) = 259; 284 
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1
H-NMR (CDCl3): δ = 7.70 (dd, J6’-5’ = 8.5, J6’-2’ = 2.1, 1 H, H6’); 7.65 (d, J2’-6’ = 1.8, 1 H, H2’); 7.32 (d, 
J5’-6’ = 8.5, 1 H, H5’); 7.31 (d, J6-8 = 2.1, 1 H, H8); 6.84 (d, J8-6 = 2.1, 1 H, H6); 5.58-5.24(m, 30 H, H19-H20,H22-H23, 
H25-H26); 2.84 (t, J=5.8, 20 H, H21, H24); 2.65-2.55 (m, 10 H, H12); 2.26-2.00 (m, 20 H, H18, H27,); 1.77-1.59 (m, 
10 H, H13,), 1.36-1.21 (m, 40 H, H14-H17,); 0.94 (t, J = 7.6, 15 H, CH3). 
 
13
C-NMR (CDCl3): δ = 172.20 CO(C5); 170.98, 170.83, 170.74 CO; 169.79 C4; 157.09 C9; 154.53 C7; 153.85 C2; 
150.80 C5; 144.70 C4’; 142.53 C3’; 134.33 C3; 133.18-127.93 C19, C20, C22, C23, C25, C26; 127.33 C1’; 126.58 C6’; 
124.05 C2’, C5’; 115.05 C10; 114.10 C6, 109.07 C8; 35.49, 34.60, 34.30, 34.25, 33.99 C12; 29.84-29.05 C14-C17; 
27.42 C18; 25.75 C24; 25.85 C21; 25.10, 24.91, 24.82, 24.67, 24.43 C13; 22.79, 20.77 C27; 14.48, 14.28 CH3. 
 
FT-IR (NaCl) 
1/λ (cm-1) Attribution 
 
3011.02; 2928.57; 2855.35 ν C sp
3 
- H 
1772.17 ν C=O 
1654.88 ν C=O α,β unsaturated 
1463.34; 1433.80 δ C=C 
1265.47; 1232.57; 1203.31; 1177.68; 1123.19 ν C-O 
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3,7,3’,4’-TETRALINOLENOYL QUERCETIN 
 
ORO
OH
OR
OR
OR
O
8
9
56
7
4
3
2
2'
3'
5'
4'
6'
1'
10
 
    
  
Reaction parameters: 
 
Molar ratio linolenil acid:quercetin  1:5 
Linolenil acid 1.65x10
-3 
mol, 0.46 g, 0.50 ml 
Oxalyl chloride 0.011 mol, 1.38 g, 0.88 ml 
Quercetin 3.3x10
-4
 mol, 0.10 g 
TEA 1.65x10
-3 
mol, 0.17 g, 0.23 ml 
Reaction temperature Room temperature 
Reaction time 20 h  
Yield  48% 
    
C87H122O11     MW = 1344.75     
 
TLC: Hexane/Acetone 9/1. In order to evidence the presence of residual quercetin, ethyl acetate 100% was 
used. 
 
m/z: 1588 [M+H]
+ 
 
UV/Vis in CHCl3     λ (nm) = 269; 301; 340 
 
O
12
13
14
15
16
17
18
19 20
21
22 23
24
2625
27
28
R =
92 
 
1
H-NMR (CDCl3): δ =12.12 (s, 1 H, OH exch. D2O), 7.73 (dd, J2’-5’ =2.1, J6’-5’ =8.2, 2 H, H2’, H6’), 7.34 (d, J5’-6’=8.2, 
1 H, H5’), 6.84 (d, J8-6 = 2.1, 1 H, H8), 6.58 (d, J6-8 = 2.1, 1 H, H6), 5.46-5.24 (m, 24 H, H19-H20,H22-H23,H25-H26); 
2.81 (t, J=5.5, 16H, H21, H24); 2.66-2.52 (m, 8 H, H12); 2.15-2.00 (m, 16 H, H18, H27); 1.78-1.56 (m, 8 H, H13); 
1.27-1.21 (m, 32 H, H14-H17); 0.94 (t, J=7.6, 12 H, CH3). 
 
13
C-NMR (CDCl3): δ = :176.52 C4; 171.29, 170.85, 170.81, 170.73 CO; 161.96 C5; 156.70 C7; 156.19 C9; 155.74 
C2; 145.00 C4’; 142.60 C3’; 132.48 C3; 132.19-127.75 C19, C20, C22, C23, C25, C26; 127.74 C1’; 126.69 C6’; 124.21 
C2’, C5’; 108.98 C10; 105.70 C6, 101.36 C8; 34.62, 34.30, 34.26, 33.95 C12; 29.83-29.24 C14-C17; 27.43 C18; 25.76 
C24; 25.86 C21; 25.08, 24.98, 24.89 C13; 22.80, 20.78 C27; 14.50, 14.30 CH3. 
 
FT-IR (NaCl) 
1/λ (cm-1) Attribution 
 
3011.23; 2928.63; 2855.47 ν C sp
3 
- H 
1771.61 ν C=O 
1655.42 ν C=O α,β unsaturated 
1487.78; 1455.55 δ C=C 
1266.37; 1235.64; 1196.68; 1179.25; 1126.98 ν C-O 
 
 
 
93 
 
3,7,(3’/4’)-TRILINOLENOYL QUERCETIN 
 
 
 
  
 
Reaction parameters: 
 
Molar ratio linolenic acid:quercetin 1:4 
Linolenic acid 1.32x10
-3 
mol, 0.37 g, 0.41 ml 
Oxalyl chloride 8.87x10
-
3 mol, 1.12 g, 0.7 ml 
Quercetin 3.3x10
-4
 mol, 0.10 g 
TEA 1,32x10
-3 
mol, 0.13 g, 0.18 ml 
Reaction temperature Room temperature 
Reaction time 20 h  
Yield 15% 
 
Using this molar ratio (1:4) both tri and tetraesters of quercetin were obtained. The two esters were then 
separated by chromatography, using a silica gel gravimetric columm (eluent hexane:acetone 9:1, ratio raw 
material/silica 1:60). 
C69H94O10     MW = 1084.32     
 
TLC: Hexane/Acetone 9/1. In order to evidence the presence of residual quercetin, ethyl acetate 100% was 
used. 
 
m/z: 1085 [M+H]
+ 
 
UV/Vis in CHCl3     λ (nm) = 270; 313; 362 
O
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1
H-NMR (CDCl3): δ = 11.64 (s, 1 H, OH exch. D2O ), 8.12 (dd, J6’-5’=8.5, J6’-2’ = 1.8, 1 H, H6’), 8.05 (d, J2’-6’ = 2.1, 
1 H, H2’), 7.36 (d, J5’-6’ = 8.5, 1 H, H5’), 6.89 (d, J8-6 = 1.8, 1 H, H8), 6.84-6.69 (s, 1 H, OH exch. D2O), 6.57 (d, J6-8 
= 1.8, 1H, H6), 5.46-5.31 (m, 18 H, H19-H20,H22-H23,H25-H26); 2.81 (t, J=5.5, 12 H, H21,H24); 2.62-2.53 (m, 6 H, 
H12); 2.15-2.01 (m,   12 H, H18, H27); 1.76-1.56 (m, 6 H, H13), 1.26-1.17 (m, 24H, H14-H17), 0.98 (t, J=7.6, 9 H, 
CH3). 
 
13
C-NMR (CDCl3): δ = 176.08 C4; 171.37, 171.14, 170.90 CO; 160.90 C5; 156.73 C7; 155.89 C9; 144.71 C2; 
144.12 C4’; 142.59 C3’; 137.34 C3; 132.20-127.33 C19, C20, C22, C23, C25, C26; 129.02 C1’; 126.24 C6’; 124.03 C5’; 
123.31 C2’; 107.20 C10; 104.79 C6, 101.48 C8; 34.65, 34.34, 34.28 C12;29.83-29.36 C14-C17; 27.43 C18;25.86 C21; 
25.76 C24; 25.16, 25.00 C13; 20.78 C27; 14.50, 14.30 CH3. 
 
FT-IR (NaCl) 
1/λ (cm-1)  Attribution 
 
3368.98 ν OH 
3010.86 ν C sp
2 
- H 
2927.77; 2854.68 ν C sp
3 
- H 
1771.16 ν C=O 
1652.15 ν C=O α,β unsaturated  
1606.40; 1491.44; 1463.99 δ C=C 
1306.08; 1266.97; 1194.39; 1127.76 ν C-O 
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4.3.2 - HPLC METHOD DEVELOPMENT 
At first, the solubility of quercetin and its esters was screened: quercetin resulted very soluble in methanol, 
whereas its derivatives were practically insoluble in methanol.  
The solubility in organic solvent was screened and quercetin esters resulted very soluble in hexane, while 
quercetin was shown to be insoluble in that solvent. This difference in solubility led to choose two different 
HPLC methods: one for quercetin and the other for its esters. 
The HPLC method employed for resveratrol was suitable also for quercetin:   
• Mobile phase: 100% methanol 
• Stationary phase: C-8 Alltima 250x4.6 mm 
• Flow rate: 0.8 ml/min 
• λ: 300 nm 
• Room temperature 
 
Initially quercetin esters were analyzed as follows: 
• Mobile phase: 99.9% Hexane and 0.1% isopropanol 
• Stationary phase: silica Ascentis 15x4.6 mm (3 μm) 
• Flow rate: 1.5 ml/min 
• λ: 254 nm 
• Room temperature 
This normal phase method overcame the solubility troubles, but it resulted in a low resolution, so the 
isopropanol percentage was slightly increased: hexane (99.8%) / isopropanol (0.2%). This composition 
allowed to achieve a higher resolution. Different stationary phases were tried as well, and the silica 
Ascentic 15x4.6 mm (3 μm) was chosen.  
The final analysis conditions were:   
• Mobile phase: 99.9% Hexane and 0.2% isopropanol 
• Stationary phase: silica Ascentis 15x4.6 mm (3 μm) 
• Flow rate: 1.5 ml/min 
• λ: 254 nm 
• Room temperature 
The chromatograms of 3,5,7,3’,4’-pentaoleoyl quercetin (Fig. 12), 3,7,3’,4’-tetraoleoyl quercetin (Fig. 13), 
3,7,3’-tri-oleoyl quercetin (Fig. 14) are reported below. 
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Figure 12. Chromatogram of 3,5,7,3’,4’-pentaoleoyl quercetin (RT= 2.933 min). 
 
 
 
 
 
 
 
 
 
 
 
  
Figure 13. Chromatogram of 3,7, 3’,4’-tetraoleoyl quercetin (RT=2.490 min). 
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Figure 14. Chromatogram of 3,7,(3’/4’)-trioleyol quercetin (RT= 3.582 min). 
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4.3.3 - LIPOSOMES 
The topical application of quercetin inhibits oxidative skin damage and the inflammatory processes induced 
by UV radiation. Low skin permeability and poor solubility of quercetin in aqueous media reduce its topical 
use: these features make the development of pharmaceutical formulations difficult. In addition to synthesis 
of prodrugs (quercetin esters), other strategies can be used in order to improve quercetin topical delivery, 
such as liposome formulation. 
In collaboration with Dipartimento Farmaco Chimico Tecnologico, University of Cagliari, quercetin and its 
derivatives were incorporated into phospholipid vesicles. The incorporation of quercetin esters into 
liposomes would allow the delivery not only of quercetin, but also of fatty acids, a class of molecules known 
to be active in the skin.  
In order to better incorporate quercetin derivatives into phospholipid vesicles, two different hydrophilic 
penetration enhancers (PEs), propylene glycol (PG) and polyethylene glycol 400 (PEG), were added to the 
formulations. Two different quercetin derivatives-loaded Penetration Enhancer containing Vesicles (PEVs) 
formulations (Formulation A e B) were produced, as reported below: 
• Formulation A: 
- Soybean lecithin (0.15 g) 
- PEG 400 (1.0 g) 
- Quercetin / quercetin derivative (0.005 g) 
- Water (1.5 ml) 
 
• Formulation B: 
- Soybean lecithin (0.15 g) 
- Propylene glycol (1.0 g) 
- Quercetin / Quercetin derivative (0.005 g) 
- Water (1.5 ml) 
 
The esters of quercetin used in these experimental formulations were: 3,5,7,3’,4’-pentastearoyl quercetin, 
3,5,7,3’,4’-pentaoleoyl quercetin, 3,7,3’,4’-tetraoleoyl quercetin, 3,5,7,3’,4’-pentalinoleoyl quercetin, 
3,7,3’,4’-tetralinoleoyl quercetin, 3,5,7,3’,4’-pentalinolenoyl quercetin and 3,7,3’,4’-tetralinolenoyl 
quercetin. 
The use of a mixture of PE/water (40% v/v) as hydrophilic phase improved the quercetin and derivatives 
solubility in water, due to their high solubilizing power, and enabled the incorporation of ~2 mg/ml of drug 
in PEVs without any sign of drug precipitation during or after fabrication. Previous findings demonstrated 
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that PEVs are powerful enhancers for dermal delivery, due to the synergistic effect of phospholipid vesicles 
and PE. 
 
4.3.3.1 - VESICLE PREPARATION  
The quercetin ester was dissolved in a PE/water solution (40% v/v) and added to a flask containing soybean 
lecithin. Lipids were left swelling in the solution overnight. Vesicles were obtained by sonicating for 3 
minutes (5 seconds on and 5 seconds off) the dispersions with a Soniprep 150 ultrasonic disintegrator (MSE 
Crowley, UK).  
 
4.3.3.2 - VESICLE CHARACTERIZATION 
Each vesicle suspension was purified from the non-incorporated drug by exhaustive dialysis against distilled 
water at 4 °C for 1 hour, using dialysis tubing (Spectra/Por® membranes: 12–14 kDa MW cut-off, 3 nm pore 
size; Spectrum Laboratories Inc., USA). Incorporation efficiency (E%), expressed as the percentage of the 
amount of drug initially used, was determined by high performance liquid chromatography (HPLC) after 
disruption of vesicles with 0.025% non-ionic Triton X-100. Quercetin content was quantified at 255 and 367 
nm using a chromatograph Alliance 2690 (Waters, Italy). The column was a SunFire C18 (3.5 µm, 4.6 × 150 
mm). The mobile phase was a mixture of acetonitrile, water and acetic acid (94.8:5:0.2, v/v), delivered at a 
flow rate of 1.0 mL/min. 
The average diameter and polydispersity index (P.I.) of the samples (6 replicates) were determined by 
Photon Correlation Spectroscopy (PCS) using a Zetasizer nano-ZS (Malvern Instrument, UK). Samples were 
backscattered by a helium–neon laser (633 nm) at an angle of 173° and a constant temperature of 25 °C. 
The P.I. was used as a measure of the width of the size distribution: P.I. less than 0.4 indicates a 
homogenous and monodisperse population. Zeta potential was estimated using the Zetasizer nano-ZS by 
means of the M3-PALS (Phase Analysis Light Scattering) technique, which measures the particle 
electrophoretic mobility in a thermostated cell. All the samples were analyzed 24 h after their preparation.  
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5 - RESULTS  
 
 
5.1 - β-SITOSTEROL 
 
5.1.1 - BIOCATALYTIC SYNTHESIS OF β-SITOSTEROL FATTY ESTERS 
The esters of β-sitosterol and fatty acid were already obtained by chemical synthesis; nevertheless, we 
synthesized these compounds using the enzymatic approach, which represents a natural way to obtain 
them.  
In the first phase of this study, five enzymes were screened: only lipases from Candida rugosa and Candida 
cylindracea resulted active. The subsequent step was to evaluate the suitability between these enzymes  
with different organic solvents, such as heptane, toluene, acetone, acetonitrile, hexane and isopropyl 
ether: among them, heptane and toluene resulted to be the most convenient. Then, different trials were 
set up at 25, 30 and 40 °C, evidencing that the esterification rate was higher at 40 °C. Finally, different 
amounts of enzyme were screened: lipase from Candida rugosa resulted more efficient at 35 U/mg, 
whereas lipase from Candida cylindracea at 14 U/mg. 
After setting up these reaction conditions, we assessed that lipase from Candida rugosa was able to esterify 
β-sitosterol with both oleic and linolenic acids, while Candida cylindracea esterified β-sitosterol with only 
oleic acid. In order to evaluate the reaction kinetics and time, three reactions in semi-preparative scale 
were performed and at fixed times (4 h, 24 h, 42 h, 48 h, 52 h, 72 h) samples were taken and analyzed using 
HPLC. 
In this step, the synthetic esters were used as reference standards for HPLC analysis. The courses of the 
biotrasformations are reported in the figures that show the amount of ester formed, calculated as area 
under the peaks in relation to time. The resulting reaction kinetics are reported below (Figures 15, 16 and 
17). 
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Figure15. Progress of the esterification of oleic acid with β-sitosterol by Candida rugosa lipase 
in relation to time  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 16. Progress of the esterification of oleic acid with β-sitosterol by Candida cylindracea 
lipase in relation to time. 
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Figure 17. Progress of the esterification of linolenic acid with β-sitosterol by Candida rugosa lipase 
in relation to time. 
 
 
As shown in the figures, the esterification of β-sitosterol with oleic acid by Candida rugosa lipase (Fig. 15) 
and by Candida cylindracea lipase (Fig 16) reaches its maximum at 24 h with a 60% yield, whereas the 
esterification of β-sitosterol using linolenic acid by Candida rugosa lipase (Fig 17) is maximum at 48 h, 
leading to a yield of 70%. Beyond these times the equilibrium of the reaction shifts towards the hydrolysis, 
due to the abundance of water in the reaction environment.  
 
RCOOH + R’OH                                RCOOR’ + H2O 
 
 
These data are confirmed by the amount of β-sitosterol during the reaction, indicated by blue lines (Fig. 15, 
16, 17).  
These results showed that lipase from Candida cylindracea is chemoselective for oleic acid. 
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5.2 - RESVERATROL 
 
5.2.1 - BIOCATALYTIC SYNTHESIS OF RESVERATROL FATTY ESTERS 
Since chemical synthesis of resveratrol mono and diesters is not possible and given the presence in 
literature of synthesis of these compounds by biocatalytic hydrolysis of triester, in the first phase of the 
study a screening on enzymes and reaction conditions was performed. This preliminary screening showed 
that a small amount of water (5%) in the reaction medium was not sufficient for promoting the triester 
hydrolysis; on the contrary, TRIS buffer/HCl (pH 8) allowed this hydrolysis. Only PPL and Acylase I from 
Aspergillus melleus were suitable to the proposed synthesis.  
Preliminary TLC analyses showed that the reaction with Acylase I from Aspergillus melleus led to the 
formation of different hydrolysis products, and in the selected reaction conditions the final amount of 
triester was low. The reaction promoted by PPL yielded to the formation of only one hydrolysis product, 
and using this enzyme there was a higher amount of triester at the end of the reaction. These results made 
us to focus on the first enzyme: hence, a semi-preparative scale reaction using Acylase I from Aspergillus 
melleus was set up in order to obtain a sufficient amount of substance for its analytical characterization. 
The reaction mixture was extracted and analyzed by HPLC (Figure 18). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 18. 
 
The HPLC/DAD analysis (Fig. 18) showed that the starting triester was still present (RT=11.55 min). Peaks at 
2.80 min, 3.60 min, 5.73 min correspond to other products in the reaction mixture. 
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In order to characterize each analyte, the raw residue (200 mg) was separated using a chromatographic 
column with 7/3 hexane/acetone as mobile phase and a 1/60 product/silica ratio. Four different fractions 
were obtained in this separation, and subsequently analyzed by MS and 
1
H-NMR. 
The first fraction (15 mg) corresponded to the starting substrate (trioleoyl resveratrol), according both to 
1
H-NMR and mass spectrometry results. The result of MS analysis of the second fraction (30 mg) was 758 
[M+H]
+
, in compliance with the molecular weight of a diester. The
 1
H-NMR analysis (Fig. 19) confirmed this 
evidence and indicated that the free -OH group was in position 4’. In fact, signals corresponding to H atoms 
in positions 2’,6’ and 3’,5’ underwent higher shifts (7.40 ppm and 6.85 ppm, respectively). Furthermore, no 
asymmetry in the signals of disubstituted ring was evidenced: if the unesterified hydroxyl group was in 
positions 3 or 5, the meta-disubstituted ring would lose its symmetry. 
 
ppm (f1)
5.0
2
.00
6
.23
4
.67
4
.08
10
.28
76
.93
9
.67
 
 
Figure 19. 
1
H-NMR spectrum of the 3,5-dioleoyl-resveratrol. 
 
The MS analysis result of the third fraction (20 mg) was 493 [M+H]
+
, which corresponds to the molecular 
weight of a monoester, whereas 
1
H-NMR analysis showed an ambiguous result, due to its low solubility. 
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The 
1
H-NMR analysis of the fourth fraction (10 mg) showed that it was oleic acid; the mass spectrometry 
yielded no results, since fatty acids are not detectable using ESI analysis. 
 
5.2.2 - ORAL BIOAVALABILITY STUDIES OF RESVERATROL AND 3,5,4’-TRIOLEOYL RESVARATROL 
 IN THE RAT 
Once the extraction procedure had been defined, resveratrol and its tri-oleoyl ester were extracted from 
rat plasma samples and analyzed by HPLC: the bioavailability results are reported in Figure 20. 
 
 
Figure 20. Bioavailability of resveratrol and 3,5,4’-tri-oleoyl resveratrol after oral administration. 
 
When administered orally, 3,5,4’-tri-oleoyl resveratrol was expected to release, at least in part, free 
resveratrol: in the plasma, however, only the presence of tri-ester was detected. In addition, as seen in 
figure 20, the oral administration of tri-oleoyl ester led to a lower bioavailability compared with resveratrol: 
hence, these results demonstrate that the oral administration of 3,5,4’-tri-oleoyl resveratrol did not 
improve the bioavailability of resveratrol. 
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5.3 - QUERCETIN 
 
5.3.1 - CHARACTERIZZATION OF QUERCETIN POLYESTERS 
In order to identify the unesterified -OH groups in the molecular structure, tetra and trioleoyl quercetin 
esters were analyzed by bi-dimensional NMR techniques, such as HMBC (Heteronuclear Multiple-Bond 
Correlation Spectroscopy), HSQC (Heteronuclear Single-Quantum Correlation Spectroscopy). Also 
pentaester was analyzed by these techniques, in order to provide a reference for tetra and triester. The 
1
H-
NMR analysis of tetra-oleoyl ester evidenced for H6 (6.61 ppm) a downfield shift compared with that of the 
corresponding pentaester (H6 6.86 ppm,); this data suggested that the 5 position could be unesterified. 
 
 
 
 
 
 
 
Figure 21. General structure of quercetin pent-esters. 
 
Furthermore, the 
13
C-NMR analysis of tetra-ester showed that C4 (174.60 ppm) had a higher frequency in 
comparison with that in the pentaester (169.25 ppm) and confirming that the hydrolized –OCO- group is in 
position 5. This hypothesis was confirmed by HMCQ and HSQC analyses.  
The identification of free hydroxyl groups in trioleoyl quercetin led to ambiguous results. The H6 and C4 
shifts allowed us to understand that position 5 was unesterified as in tetra-ester, while the comparison 
between the H6’, H2’,.and H5’ shifts in penta and tetraester (7.73, 7.69 and 7.32 ppm) with that in triester  
(8.14,  8.08 and 7.38 ppm) allow to hypnotize that the second free -OH group could be either in 3’ or in 4’ 
position. Not even 
13
C-NMR and 2D-NMR techniques were able to distinguish which position was 
unesterified.   
Thus, computational studies, in collaboration with Dr. Contini, Dipartimento di Scienze Molecolari Applicate 
ai Biosistemi, University of Milan, were performed. To make the calculation easier, the studies were 
performed on quercetin acetylated esters: 3,5,7,3’,4’-pentaacetyl quercetin, 3,7,3’,4’-tetraacetyl quercetin, 
3,7,3’-triacetyl quercetin and 3,7,4’-triacetyl quercetin. Penta and tetraesters were included in the study to 
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rule out any systematical error. Initially, a conformational research ( molecular mechanic, lowmode 
method, ff MMFF94x, gas phase) was performed and eight of the most stable conformation were chosen 
for both quercetin triacetyl esters, while for penta and tetraester only the most stable conformation was 
selected. Then, the geometry  optimization of molecules was performed following a quantum mechanical 
method (DFT mPW1B95/6-31+G(d,p)) and either 
1
H- and 
13
C-NMR analyses were simulated for all the 
selected conformations (GIAO method, mPW1B95/TZVP). The results of the computational study were 
fitted with the experimental values on a regression curve, and regression coefficients (R
2
) were calculated 
for both 
1
H- and 
13
C-NMR. Figure 22 shows the regression curve obtained comparing the 
1
H-NMR calculated 
values for 3,7,4’-triacetyl quercetin vs experimental values, while the comparison between the calculated 
data for3,7,3’-triacetyl quercetin and the experimental results are displayed in Figure 23. 
 
 
 
Figure 22. Regression curve of 3,7,4’-triacetyl quercetin calculated values vs. experimental values. 
 
 
 
Figure 23 . Regression curve of 3,7,3’-triacetyl quercetin calculated values vs. experimental values. 
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As seen in Figure 22, the regression curve of 3,7,4’-triacetyl quercetin reported a R
2
 value of 0.972, while 
for 3,7,3’-triacetyl quercetin the R
2
 value is 0.996 (Figure 23): this data indicate that the unesterified 
hydroxyl group of the synthesized quercetin triester could be more probably in position 4’. The data from 
computational study on
 13
C-NMR, however, were not indicative to assess whether the free -OH group was 
in position 4’ or 3’; these ambiguous data could be due to the molecular conformation, hence, other 
computational studies are still in progress. 
 
5.3.2 - LIPOSOMES 
As an example, the results of pentaoleoyl and tetraoleoyl esters incorporation in liposomes are displayed in 
Table 10. 
Mean size of PEVs, measured by PCS, was around 200 nm for all the loaded formulations, which were 
always larger than the empty ones. The difference in size between empty and corresponding loaded 
vesicles was related to the composition of the samples. 
PEVs were quite homogeneously dispersed and values were always repeatable. Zeta potential values were 
always highly negative (around –50 mV), indicative of a good storage stability against vesicle aggregation 
and fusion. Drug incorporation into the vesicles at a percentage ranging from 44 to 57 was achieved by all 
the prepared formulations, showing their good loading capacity. 
 
 
  MD(nm) P.I. ZP (mV) E (%) 
Lecithin/PG Empty 57 ± 10 0.30 –51 ± 7  
 
Pentaoleolyl 
quercetin 
183 ± 10 0.35 –64 ± 4 57 ± 8 
 
Tetra-oleolyl 
quercetin 
195 ± 5 0.30 –52 ± 2 44 ± 9 
Lecithin/PEG Empty 153 ± 10 0.28 –51 ± 4  
 
Penta-oleolyl 
quercetin 
186 ± 5 0.29 –32 ± 3 55 ± 6 
 
Tetra-oleolyl 
quercetin 
205 ± 6 0.19 –51 ± 6 45 ± 4 
      
Table 10. 
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5.4. - ANTIOXIDANT ACTIVITY 
 
The antioxidant activity of resveratrol, quercetin and their respective esters was assessed by ABTS and 
DPPH assays. For ABTS assay the results were expressed as TEAC, whereas for DPPH assay as IC50. These 
tests were selected since they are the most used to assess  the antioxidant activity of polyphenols. 
The results relevant to the antioxidant activity of resveratrol tri-esters are shown in Figures 24 and 25. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 24. ABTS assay: antioxidant activity of resveratrol tri-esters expressed as TEAC. 
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Figure 25. DPPH assay: antioxidant activity of resveratrol tri-esters expressed in IC50. 
As seen in Figures 24 and 25, ABTS assay show that the triesters with saturated fatty acids (tripalmitoyl and 
tristearoyl resveratrol) have a higher activity than esters with unsaturated fatty acids, while DPPH assay 
shows opposite results. However, differences in antioxidant activity resulting from ABTS assay among 
resveratrol esters could not be considered significant, since their results were of few ng TEAC/μg 
substance: data expressed in such small units are more probably subject to errors. In addition, the 
dissolution medium used in ABTS assay contained a considerable amount of water: resveratrol esters are 
scarcely soluble in such solvent, hence it could jeopardize the results of this test. On the contrary, DPPH 
assay could be considered more reliable, as the medium was mainly ethanol, which allows a better 
dissolution of resveratrol tri-esters. In addition, the DPPH results showed larger differences among 
resveratrol esters antioxidant activity. In conclusion, we can state that resveratrol esters with unsaturated 
fatty acids show a more potent antioxidant activity compared with saturated fatty acids esters.  
Both of the assays performed displayed a significantly lower activity of the tri-ester compared with 
resveratrol: this result shows that the -OH groups of resveratrol have a key role for its antioxidant activity.  
In addition, preliminary tests on 3,5-dioleoyl resveratrol showed a higher antioxidant activity in comparison 
with 3,5,4’-trioleoyl resveratrol. 
 
The results relevant to the antioxidant activity of quercetin esters are shown in Figures 26 and 27. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 26. ABTS assay: antioxidant activity of resveratrol tri-esters expressed as TEAC. 
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Figure 27. DPPH assay: antioxidant activity of resveratrol tri-esters expressed in IC50. 
 
As seen in the Figures reported above, both assay showed that the difference in antioxidant activity 
between penta and tetraesters with the same fatty acid was not considerable. This evidence indicate that -
OH group at position 5, which is free in all analyzed tetra-esters, is not essential for the antioxidant activity 
of quercetin. The higher activity of pentastearoyl quercetin resulting from both assays could be explained 
by its hydrolysis. As for resveratrol, also quercetin in both assays displayed a dramatically higher 
antioxidant activity compared with its esters. 
 
These data show that the synthesis of esters is intended mainly to enhance the absorption and 
permeability properties of polyphenols; once absorbed, the esters are supposed to hydrolyze and release 
free polyphenols. 
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